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“Born there”  
A poem by Dr Curi Kim(1) 
(This poem was inspired by a patient with drug-resistant tuberculosis) 
 
Birth geography 
Tied tight to longevity 
But when might is right 
What rights are given that might 
Right the balance of the world 
No rites can heal this 
Hideous haemoptysis 
If a mite of care 
The mighty felt to fight white 
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The Palliative Care needs of patients with Drug-Resistant Tuberculosis (DR-TB) are under-researched, 
yet pertinent in the management and control of DR-TB. Most literature reviewed focused on treatment 
schedules, outcomes, transmission, drug adherence, drug side effects and further drug-resistance.  
Aim 
The aim was to determine the palliative care needs of patients infected with DR-TB living in the 
Southern sub-district of Cape Town. 
The Objectives 
The objectives were to determine the quality of life and symptom burden of DR-TB patients and to 
assess for correlation between these variables and palliative care needs. 
Methodology 
In this cross-sectional study, twenty-eight participants were posed a culturally sensitive questionnaire 
designed by the researcher, that comprised: demographic questions, Likert-type questions for the 
African Palliative Care Association – Palliative Outcome Score (APCA-POS) tool, Eastern Co-operative 
Oncology Group (ECOG) score, a symptom checklist and open patient dignity questions. Quantitative 
and qualitative data of the respondents’ quality of life, functional status and burden of symptoms in the 
preceding week were ascertained. Pre-determined numerical scores in the Likert-type questions were 
deemed indicative of palliative care need. 
Results 
Quantitative and qualitative analysis of the data showed that each participant had a palliative care need: 
be it either (or a combination of) unmet clinical, psychological, social and/or spiritual needs - despite 
being at differing stages of the DR-TB disease trajectory. These needs required contextualizing within 
the respondents’ communities where socio-economic issues were prevalent. Predominant physical 
complaints were tiredness (79%), joint pain (64%), confusion (61%) and shortness of breath (51%). 
Respondents’ also experienced a loss of autonomy, poor self-value and financial insecurity. Fifty 
percent of patients interviewed required urgent further management and referral to the local clinic.  
Conclusion 
Despite the small cohort of patients and possible recruitment bias, this research concurred that a 
palliative care approach be adopted from the point of DR-TB diagnosis and throughout the treatment 
period – regardless of treatment outcome; and that DR-TB patients had significant unmet palliative care 








Robert Koch identified Mycobacterium tuberculosis on the 24th March 1882. (2) This bacterium was 
responsible for “consumption” (the older description of pulmonary tuberculosis) and the “White plague 
of Europe” (a depiction of its devastating effect on seventeenth to nineteenth century England, America 
and Europe).(3) Even today, 135 years since discovery, Mycobacterium tuberculosis infection is the 
leading natural cause of death in South Africa(4) and it remains one of the top ten causes of death 
worldwide in 2015 (5) – resulting in the deaths of three people per minute.(6)  
 
Tuberculosis has also been described “like the multi-layered mystery of the famous Russian doll. No 
sooner do we think we understand it, than a new form, as baffling and menacing as ever, appears to 
confound us.”(3) This “White Plague” has morphed into two categories: drug-sensitive (DS-TB) and 
drug-resistant tuberculosis (DR-TB). Table 1 on page 12 provides definitions for DS-TB and DR-TB. 
 
 
Figure 1: Russian Matryoshka nesting dolls(7) 
 
1.2 The development of DR-TB 
Patients either acquire DR-TB infection de novo from a DR-TB contact* (implying person-to-person 
transmission), or their DS-TB infection may develop subsequent drug resistance due to poor adherence  
 
___________________________________________________________________________________ 
*A “contact”: any person who has been exposed to an index patient(8) 
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to standard anti-tuberculosis medication, sub-optimal treatment due to health-system or patient-related 
factors (such as drug stock shortfalls, poor implementation of treatment guidelines or transport costs(9)), 
pharmacokinetic variability (even with excellent adherence and stringent supervision(10)) or the 
circulation of counterfeit drugs. (11,12)   
 
In the South African context, other contributing factors have been implicated: poor therapeutic 
relationships between patients and health care personnel (HCP), inadequate adherence counselling, 
inadequate contact tracing and follow-up of DR-TB cases and restricted access to health care.(8) 
 
A more profound basis for the development of DR-TB, was the indictment made by the University of 
Cape Town (UCT)’s Professor Dheda and international colleagues: that DR-TB had resulted “essentially 
[as] a consequence of a systematic violation of human rights arising from the failure to develop 
pharmaceuticals for this neglected disease.” (13,14)   
 
1.3   The Emergence of DR-TB 
Progressively, DR-TB has been further sub-divided to encompass Rifampicin-Resistant (RR-TB), Multi-
Drug Resistant (MDR-TB), extensively drug-resistant (XDR-TB), extremely drug-resistant(15) and 
totally drug-resistant tuberculosis (TDR-TB). The definition for drug resistance beyond extensively 
drug-resistant tuberculosis has not yet been agreed upon amongst the international community. (15)   
Table 1 below explains the sub-divisions of DR-TB according to their resistance patterns. 
 
    Table 1. Definitions for Drug-resistant TB(16) 
Acronym Definition Resistance pattern 
DR-TB Drug-resistant TB  Resistance to any TB drug 
RMR-TB Rifampicin mono-resistant TB  Resistance to rifampicin and susceptibility to isoniazid 
MDR-TB Multi-drug resistant TB TB resistant to isoniazid and rifampicin 
RR-TB Rifampicin-resistant TB TB resistant to rifampicin, regardless of resistance to other 
drugs 
PreXDR-TB Pre-extensively resistant TB MDR-TB with resistance to either a fluoroquinolone OR a 
second-line injectable 
XDR-TB Extensively drug-resistant TB MDR-TB with resistance to both a fluoroquinolone AND a 
second-line injectable drug 
     
 
MDR-TB had first been recognised in the United States in 1976, (17)  and in the proceeding forty years 
had come to be reported in a further 153 countries. (18)  MDR-TB describes Mycobacterium 
tuberculosis infection exhibiting in vitro resistance to both first-line drugs, Isoniazid and Rifampicin. 
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(19) The medical literature described MDR-TB as a “leading killer”, (20)  an “epidemic”, (21)  a “public 
health menace”, (22)  “a dirty disease”, (20)  a “global threat” (21)  and a “real and present danger for 
the developed nations”. (23) Those tuberculosis patients with MDR-TB have been considered as being 
“some of the most vulnerable persons”, (24)  “therapeutically destitute” (25)  and “hopeless”. (25)   
 
The term XDR-TB first appeared in 2006 in a report jointly published by the US Center [sic] for Disease 
Control and Prevention (CDC) and the World Health Organization (WHO). (26)  Recent medical 
literature described XDR-TB as a “burgeoning global health crisis” (15)  and a “new threat” (15)  that 
“has a high mortality rate regardless of HIV status”. (15) 
 
The term DR-TB is used in this research study to include mono-, multi-, pre-extensively, extensively 
and totally drug resistant tuberculosis. 
 
1.4   The Incidence of DR-TB 
In 2014 the WHO estimated that 480 000 people developed MDR-TB worldwide and that there were an 
estimated 190 000 deaths from MDR-TB. (27)  South Africa’s incidence of laboratory-confirmed R-
R/MDR-TB cases in 2014 was 18 734. (28)   
 
According to the WHO Global Tuberculosis Report 2015, (29) 1.8% of new TB cases notified globally 
were MDR-TB, and 6.7% of re-treatment TB cases were MDR-TB. XDR-TB had been reported in 105 
countries in 2015 and an estimated 9.7% of people with MDR-TB had XDR-TB. (27)   
 
The WHO Global Tuberculosis Report 2016 (5) considered South Africa to be a high burden TB 
country, ranking 6th in 2015, with a total TB incidence of 454 000. South Africa had the highest HIV-
positive TB incidence (258 000). This Report estimated 480 000 new cases of MDR-TB and an 
additional 100 000 people with RR-TB who were newly eligible for MDR-TB treatment. South Africa 
was one of fourteen countries that had the highest TB, MDR-TB and TB-HIV incidence. 
 
Figures released recently in the WHO Global Tuberculosis Report 2017,  (30)  indicated that in South 
Africa: 3.4% of new TB cases were found to be MDR/RR-TB and 7.1% of previously treated cases (30); 
globally, the percentages were 4.1% and 19% respectively. (30)  An estimated 600 000 incident cases of 
MDR/RR-TB were reported worldwide in 2016- 490 000 of which were MDR-TB and approximately 
240 000 deaths due to MDR-TB. In that same year, the average proportion of MDR-TB cases globally 
with XDR-TB was 6.2%. 
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The schematic below depicts the incidence of MDR-TB and XDR-TB in the Western Cape from 2007-
2010. (31)  MDR-TB and XDR-TB data relevant to the Western Cape subsequent to 2010 was not 
available. 
 




In South Africa, 80% of MDR-TB(32) and an increasing proportion of XDR-TB(33) infections are 
acquired de novo. The emergence of additional resistance to the drugs available in the national 
programme to manage XDR-TB has resulted in patients who are essentially untreatable. (34)  Some 
patients have nowhere to go and remain in TB facilities in South Africa. (15)  Pietersen et al. (33)  
reported that since 2008 in the Western Cape, approximately 100 of such patients had been discharged 
back into the community – for reasons such as absence of effective drugs, treatment futility, scarce 
resources and insufficient bed space. (15)  In their communities, these incurable XDR-TB cases 
continued to live for a number of months (more than 50% survived for an average of 16 months(34)) 
and continued to engage in family, community and work life. (15)  These discharged patients, however, 
remain infectious and potential vectors for transmission (35) - thereby threatening to undermine national 
and international TB control efforts. (34)  Having had TB drugs discontinued, the need for palliative 
care is acute and maintaining contact with the health system critical. (14)  However, these patients often 
find themselves abandoned by HCPs and in a “careless void”. (25)  This was sensationalized in a 
national newspaper in December 2016, reporting: “TB sufferers sent home to die, and perhaps to kill”. 
















1.5   Treatment Outcomes and Mortality 
Undoubtedly, DR-TB is a “life-threatening condition” (37)  upon diagnosis, with an extended course 
and unpredictable prognosis. (21)  According to Dheda et al the number of drugs a Mycobacterium 
tuberculosis isolate was resistant to independently predicted mortality - therefore, DR-TB patients had 
poorer outcomes than those ptients with DS-TB. (13,15)  They noted that DS-TB patients had higher 
survival and cure rates than MDR-TB patients and similarly, MDR-TB had higher successful cure rates 
than XDR-TB. (15)   
 
The schematic below illustrates the global MDR-TB treatment outcomes from 2007 to 2012 – and 
demonstrates that the treatment success rate remained relatively unchanged in this time period. 
 
  Figure 3: Global MDR-TB treatment outcomes: 2007-2012 (38) 
  
The latest treatment outcomes data for South Africa showed a treatment success rate of 81% for new 
and relapse DS-TB (2015 cohort), 54% for MDR/RR-TB (2014 cohort) and 27% for XDR-TB (2014 
cohort). (30)  Globally, the treatment success rates for the same parameters were 83%, 54% and 30% 
respectively. (30)   
 
As compared to the global treatment success rates over a similar period, the schematic that follows 
shows an encouraging improvement in treatment success rates. However the number of patients lost to 






   Figure 4: South African MDR-TB treatment outcomes: 2009-2012(38) 
 
In the Western Cape, the treatment success rate of DR-TB patients had marginally improved year on 
year, however in 2012 remained less than 30% - see Figure 5. (39)  
   Figure 5: Western Cape DR-TB outcomes: 2009-2012(39) 
  
 
Figure 6 illustrates the worse outcomes for XDR-TB nationally. 
Figure 6: South African XDR-TB treatment outcomes: 2009-2012(38) 
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The sturdiness of the global, national and local health systems is potentially jeopardised by the DR-TB 
epidemic (21) - with this “profound challenge” (40)  in the management and containment of DR-TB 
having been likened to “defusing… a time bomb”. (25)  In order to institute the necessary “effective and 
humane response”, (21)  Abubakar and colleagues urged for “major conceptual change and visionary 
global leadership”. (23) 
 
1.6   Treatment regimens 
“Effective” DR-TB regimens are obligated to aim for cure and include targeted anti-tuberculosis drugs 
recommended by WHO and national guidelines, with a large number of active drugs (particularly later-
generation fluoroquinolones). The regimen must be individualised according to the patient’s 
Mycobacterium tuberculosis isolate and concomitant medical conditions, with concurrent use of anti-
retrovirals (ARVs) if HIV-positive. A community-based model of care is recommended. (15) 
The WHO Global Tuberculosis Report 2016 (5) recommended that “RR-TB” and “MDR-TB” patients 
be grouped together and collectively referred to as MDR/RR-TB. (5) These MDR/RR-TB patients were 
to be treated with the second-line MDR-TB regimen. (41)  Historically, DR-TB treatment was 
prolonged (lasting approximately 20 months), expensive (swallowing approximately 45% of the South 
African national tuberculosis management budget), (42)  required toxic drugs and offered a low success 
rate for cure. (29)  In May 2016, the WHO launched new guidelines for the management of MDR-TB 
with the recommendation of a shorter 9 to12 month regimen. (43)  This shorter regimen has promised to 
cost less, have lower mortality, lower loss to follow-up rates and potentially achieve a success rate of 
>90%.(5)  
 
Subsequently, the shorter regimen was rolled-out to Cape Town patients on 01.10.2017 and initiated at 
primary health care clinics. Unlike the WHO recommendations, the local rollout program also included 
pregnant patients, those with mild extra-pulmonary disease and previously fully treated and cured MDR-
TB patients whose isolate remained sensitive to second line drugs. (Naidoo, G. 2018, personal 
communication, February 6). 
 
The efficacy and durability of this new regimen is still being investigated.(44) 
  
1.7   The Challenge 
The treatment challenges and “patient-level factors” (35)  have to be addressed as they influence the 
adherence, continuity of care, treatment outcomes and ultimately infectious control of DR-TB. (22)   
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The WHO identified DR-TB as an adult disease that required palliative care (45): In Isaakidis’ study in 
Mumbai, India, patients and their families described DR-TB as “the worst of the worst illnesses” and its 
treatment “worse than the disease itself”. (46)  The response to the suffering caused by the DR-TB 
epidemic, according to Harding et al. needed to be both “effective and humane” (21)  and Lopez et al 
(47) suggested that effective care include recognising the dignity and individuality of the person with 
TB – thereby investing in knowing the patient and not merely their diagnosis. (47)   
 
The Oxford Dictionary defined “humane” as: “having or showing compassion or benevolence” or 
“inflicting the minimum of pain”. (48)  The WHO definition of palliative care encapsulates the requisite 
“humane” response: “Palliative care is an approach that improves the quality of life of patients and 
their families facing the problems associated with life-threatening illness, through the prevention and 
relief of suffering by means of early identification and impeccable assessment and treatment of pain and 
other problems, physical, psychological and spiritual”. (49) 
 
The WHO definition of Palliative Care (49) offered reasons why DR-TB patients would benefit from 
receiving palliative care, in that it: 
▪ “provides relief from respiratory distress, pain and other symptoms; 
▪ affirms life and regards dying as a normal process; 
▪ intends neither to hasten nor to postpone death; 
▪ integrates the psychological and spiritual aspects of patient care; 
▪ offers a support system to help patients live as actively as possible until death; 
▪ offers a support system to help the family cope during the patients’ illness and in their own 
bereavement; 
▪ uses a team approach to address the needs of patients and their families, including bereavement 
counselling, if indicated; 
▪ enhances quality of life, and may also positively influence the course of illness; and 
▪ is applicable early in the course of illness, in conjunction with second-line anti-TB medication, 
with the main therapy intended to prolong life through cure”.(50) 
 
The last point related to when palliative care would be applicable in DR-TB management. The benefits 
of early integration of palliative care in the course of a life-threatening illness, was investigated by 
Temel et al in their study entitled, “Early Palliative Care for Patients with Metastatic Non-Small-Cell 
Lung Cancer”. (51)  “Early” implementation was interpreted as at the time of diagnosis - and palliative 
care was found to lead to significant improvements in both quality of life and mood.  
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In DR-TB patients, the pragmatic timing of palliative care integration is an imperative ethical obligation 
for national health departments with limited resources. The WHO promulgates a “needs-based” model 
of palliative care, rather than a “prognosis-based” model. (52) That does note imply that palliative care 
be postponed until the identification of risk factors for mortality in DR-TB.  
 
With regards to the delivery of effective care, Mason and colleagues urged HCPs to have a “greater 
competency in understanding the social and cultural dimensions that impact TB patients.” (53)  
Furthermore, instituting a “humane” response requires TB to be recognized as “more than just a 
biomedical phenomenon”, (20)  as it also undermines the TB patient’s “sense of self and personhood”. 
(47)  TB must be fully comprehended for the suffering it inflicts upon those already burdened by 
poverty, overcrowding, malnutrition and inadequate health care access. (20)  Thus, a humane response 
demands a holistic, palliative care approach to appreciate the DR-TB patient’s perspective within their 
community and context.(54,55) 
 
In it’s 2016 Treatment Guidelines for Drug-Resistant Tuberculosis policy, the WHO recommended that 
“palliative and end-of-life care in patients with very advanced resistance patterns” be a research priority 
and that more studies be conducted on health-related quality of life.(5) 
 
This research study evaluated the impact of DR-TB and its treatment on the quality of life and burden of 
symptoms experienced by DR-TB patients in the southern sub-district of Cape Town. The findings 
contributed to knowing more about the multi-dimensional palliative care needs of DR-TB patients and 
allowed the researcher to assess for correlation between the entities of quality of life and symptom 
burden to the need for palliative care. This study aimed to highlight the necessity and ethical obligation 
for palliative care services to be made available in the southern sub-district of Cape Town (and beyond).  
 
The Clinical Investigator is referred to as the “researcher” and the Principal Investigator as the 
“supervisor” in the text, with the terms “participants”, “patients” and “respondents” used 
interchangeably to refer to the DR-TB patients who participated in the study. 
 
This introductory chapter provided background on the emergence of DR-TB, the challenge its treatment 
poses and the poor treatment outcomes reported historically. The need for palliative care alongside 
curative treatment strategies has been introduced and its merits documented. The next chapter reviews 
the international and local literature pertaining to quality of life, functional status, symptom burden and 




Literature Review  
___________________________________________________________________________________ 
2.1   Overview 
Chapter 2 presents the findings of an extensive literature search on DR-TB and Palliative Care - and 
exposed the paucity of data on the palliative care needs of DR-TB patients. The literature findings of the 
general benefits of palliative care, the optimal timing of integration of palliative care and the causes of 
clinical deterioration of DR-TB patients are discussed within the context of a low-resource setting, with 
emphasis on cultural sensitivity. Palliative Care needs were further investigated with respect to literature 
pertaining to quality of life, functional status and symptom burden of DR-TB patients – and the 
assessment tools utilised in this regard. This formed the basis of the questionnaire designed for this 
research study. The rationale proposed by the researcher was validated by the corpus of literature.  
 
2.2   Literature search methodology 
A Literature search was undertaken using the EBSCO host database platform: Africa-wide information, 
ATLA Religion database with ATLASerials, CINAHL and MEDLINE. The keywords and phrases used 
to search thematically included: “quality of life”, “symptom burden”, “multi-drug resistant 
tuberculosis”; “MDR-TB”; “TB”; “tuberculosis”, “extensively drug-resistant tuberculosis”, “XDR-TB”; 
“psychosocial”, “stigma”, “palliative medicine”; “palliative care”; “Western Cape”; “South Africa”; 
“morbidity”; “adverse drug reactions”; “cultural competency” and “dignity”. The literature reviewed 
was not limited to all these keywords being present simultaneously as the body of literature would have 
been too small. Additional articles were found by scanning reference lists found in the initial search and 
those cited in journal articles. The Oxford Textbook of Palliative Medicine(56) was also referred to. 
 
Other resources that were consulted to broaden knowledge of DR-TB were the MDR-TB treatment 
guidelines set out by the South African Department of Health’s National TB management guidelines, 
(19)  the Companion Handbook to the WHO Guidelines for the Programmatic management of Drug-
Resistant Tuberculosis, (50)  The Patient’s Charter for Tuberculosis Care, (57)  the Declaration on 
Palliative Care for MDR/XDR Tuberculosis (see Appendix 1), (37)  Hospice Palliative Care Association 
(HPCA) of South Africa’s Guidelines for providing palliative care to patients with tuberculosis, (58)  the 
End TB Strategy (2016-2035) (see Appendix 2),  (59)  the Western Cape Annual Progress Report 
2014/15: Provincial Strategic Plan 2012-2016,  (39)  Drug Resistant Tuberculosis in South Africa: 
findings from a nationwide survey, 2012-2014, (60)  and the Report of the Evaluation of South Africa 
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Drug-resistant TB programme and its implementation of the Policy Framework on Decentralised and 
De-institutionalised management of Multidrug resistant TB. (38)  Drug-resistant Tuberculosis by the 
Lancet Respiratory Medicine Commission, March 2017 (61) was an excellent resource. To gauge the 
magnitude of the DR-TB problem globally and locally, statistical data available in the Global 
Tuberculosis Report 2015,  (29)  2016, (5) and 2017, (30)  Global TB Fact sheet 2015 (27) and the 
Western Cape Mortality profile (62) were consulted. 
 
Various websites were visited: tbsouthafrica.org; The International Union against TB and Lung disease 
(IUATLD) www.theunion.org; www.who.int/tb. The researcher also attended the Advanced course, 
“Meeting the challenge of drug resistant tuberculosis” held in Cape Town on 24-26 March 2017. The 
conference afforded opportunity to hear leaders in the field of DR-TB discuss treatment challenges and 
new drug developments. Despite the focus on curative management, there was active discussion 
regarding the dilemma of untreatable TB and debate regarding sanatoria or community-based palliative 
care. 
 
2.3   Gaps in the Literature 
Following this comprehensive search, it was evident that the palliative care needs of DR-TB patients 
were poorly represented within the literature - despite DR-TB’s irrefutable life-threatening nature and 
four-decade existence. The mainstay of the literature reflected public health prerogatives. Volumes of 
literature were available regarding the epidemiological, microbiological and genetic make-up of DR-TB, 
future vaccine and drug development, adverse drug reactions, the global extent of the DR-TB problem 
and the clinical outcomes reported for DR-TB. (63)   
 
Nonetheless, there was limited research of the patients’ experience of DR-TB and the psychosocial 
context of DR-TB. (22)  The impact of DR-TB infection and its treatment on the patients’ quality of life, 
(64)  functionality, (65)  spiritual wellbeing (63) and the nature and severity (21,66) of their palliative 
care needs were neglected in the literature.  
 
The researcher noted that the literature concerning quality of life of DR-TB patients placed more focus 
on the adverse drug reactions of the DR-TB treatment and not the combined effect of the infectious 
disease process and the drug therapy. Many studies evaluated the symptom burden and quality of life of 
patients co-infected with HIV and DR-TB, but not of DR-TB alone. Further knowledge gaps were noted 
in the symptom prevalence and burden of DR-TB patients(21) and the reasons for DR-TB patients 
dying, irrespective of HIV status or phase of treatment.(67) 
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In addition, the researcher was unable to locate an assessment tool for determining palliative care needs 
of DR-TB patients, nor able to find a scoring system for evaluating the TB patient’s degree of 
morbidity.(68) Furthermore, the DR-TB literature did not yield realistic suggestions for implementation 
of palliative care according to an assessment of needs. 
 
Several countries with the highest incidence of DR-TB were not well represented in the English 
literature - particularly Russia, China and India. This was evident in Bauer’s systematic review(24) 
where three potentially relevant Russian articles were excluded from analysis. Thomas et al described 
the shortage of studies originating in low and middle-income countries as a “dearth”. (22)   
 
2.4   Palliative care needs 
A relevant South African study published in the latter part of 2016, entitled, “What palliative care-
related problems do patients with drug-resistant or drug-susceptible tuberculosis experience on 
admission to hospital? A cross-sectional self-report study” (66)  was reviewed. The authors (Harding et 
al.) commented that their literature search had also failed to identify data on patient-reported palliative 
care needs in DR-TB patients.  
 
Their study utilised a self-report questionnaire that included the African APCA POS tool to identify the 
most burdensome problems in the physical, psychological, social and spiritual domains. The aim was to 
compare palliative care-related problems in DS-TB versus DR-TB patients when these patients were 
admitted to hospital. However, the circumstances for admission were different: DS-TB patients were 
admitted for TB complications and DR-TB patients for initiation of treatment (prior to decentralised 
management). 
 
In the researcher’s opinion, use of the term “palliative-care related problems”, might hold negative 
connotations for those unfamiliar with palliative care - creating the impression of a separate, additional, 
onerous entity to care providers. The introductory paragraph described a number of TB, MDR-TB and 
XDR-TB statistics without clear context, and included a disingenuous statement that, “Palliative care is 
needed for those who may die from their TB infection, especially XDR-TB”. (66)  The Declaration on 
Palliative Care and MDR/XDR-TB, (37)  proposed that palliative care be integrated alongside the 
prevention and treatment of MDR/XDR-TB, and from the time of diagnosis until the patient reached 
cure or the end of life – and thus regardless of treatment outcome. 
 
The study’s findings were possibly limited by sampling bias and underestimation of symptoms by 
excluding those too ill to participate. This exclusion was based on a professional nurse’s clinical 
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judgment, which was not quantifiable and perhaps not reproducible. With consecutive sampling these ill 
patients were prohibited from being re-approached when feeling more able, which excluded the yield of 
valuable information of those with potentially the greatest “problems”. Another limitation was that other 
co-morbidities or confounding variables on functional performance were not included. The inclusion 
criteria did not state whether patients had pulmonary or extra-pulmonary TB or whether patients were 
admitted for other complications (such as HIV) and were subsequently found to have TB. Interviews 
were done within 7 days of admission and although improvement might have occurred having started 
treatment (contrasting Chang et al’s systematic review findings that symptomatic improvement only 
started 2-3 weeks into treatment(63)) - other research pertaining to DR-TB found that the treatment 
(especially the injectables) per se caused increased morbidity, (69)  which was not mentioned in this 
study.  
 
The study did not mention any delays for the hospital admission of DR-TB patients (due to bed 
availability) and thus a delay in treatment. (More recently in South Africa, DR-TB treatment initiation 
has been decentralised with the aim of starting treatment within five day of diagnosis(19)).  
 
Separate DS and DR-TB African APCA POS scores were not reported in the paper for the comparitive 
scores to be seen. The researcher had reservations about the reasonability of drawing conclusions about 
DR-TB patients’ palliative care needs by comparing newly admitted DS-TB patients experiencing 
complications, with DR-TB patients forcibly admitted to hospital for treatment initiation.  
Harding et al.’s study found that the “worry”question in the APCA POS scored the worst for the full 
sample of DS-TB and DR-TB patients; and that the diagnosis of DR-TB was predictive of lower (better) 
scores for both total POS and Factor I (physical and psychological wellbeing). That would imply that 
DR-TB patients experienced fewer palliative care needs than DS-TB patients. Bauer, (24)  Brown, (69)  
Ahmad,(64) and Sharma’s(70) studies contradicted these findings and therefore the researcher 
questioned the validity of this study design. 
 
Regardless of the study’s shortfalls, it identified some of the multidimensional problems TB patients 
(both DS and DR-TB) experienced when admitted to hospital and advocated for the training of HCPs to 
assess and manage these complex problems in the inpatient setting. Importantly the authors also 
mentioned the necessity of addressing palliative care problems within the community prior to admission 
to hospital and after discharge, to ensure continuity of care. 
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The scarcity of palliative care needs literature with respect to DR-TB re-directed the focus of the 
literature search to studies relevant to the evaluation of quality of life, functional status, symptom 
burden and dignity maintenance in DR-TB patients – the combination of which would estimate 
palliative care need in this research. Some of the key articles found in the literature search have been 
discussed below - some relate to TB broadly, some to DS-TB from which inferences regarding DR-TB 
can be made, and others to DR-TB specifically. 
 
2.5   Quality of life in TB patients  
Quality of life (QoL) or Health Related Quality of Life (HRQoL) assessment is an important health 
outcome. It is relevant in understanding the impact of TB(24) and its treatment on the patients’ 
subjective sense of overall wellbeing. (71)   
 
Chang et al’s systematic review entitled “Quality of life in tuberculosis: A review of the English 
language literature” (63)  published in 2004 was informative. The authors recognised that little 
literature was available on TB patient’s quality of life and illness burden, as well as QoL variations with 
respect to being on treatment or achieving cure. They suggested that knowing more about these entities 
would “improve treatment regimens, adherence to treatment, functioning and well-being of people with 
TB.” (63)  No mention was made in the selection criteria of whether DR-TB literature was included 
(although this is presumed as DR-TB treatment was mentioned further on) – and no distinction was 
made between DS-TB and DR-TB in their results or comments. Sixty articles met their inclusion 
requirements from their search on PUBMED using 12 appropriate medical subject headings (MeSH) 
terms. The authors’ initial definition of QoL focused on physical and psychosocial health, social and 
role functioning and self-perceptions of health – but led to the concession in the reviewing process that 
“TB-specific QoL domains” (63)  of spiritual and financial wellbeing, should have been included. The 
authors divided their literature findings into the following domains: somatic symptoms; physical, 
psychological, social and emotional functioning; role function, general health perceptions, as well as 
spiritual and financial wellbeing. Chang’s systematic review did not find any studies describing the 
impact of TB symptoms, diagnosis or drug therapy on functional status. (63)  At the time of their 
review, a TB-specific QoL instrument was not available and Chang et al advised future investigators to 
use “generic QoL instruments or batteries of available instruments.” (63)  So too, they emphasised that 
in resource-limited settings (thus relevant to the study in the southern sub-district of Cape Town), 
financial and spiritual domains should be included. The authors admitted to having unanswered 
questions with respect to whether the QoL differed between DS-TB and DR-TB patients and whether 
QoL contributed to the development of resistant disease.  
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In 2013, a systematic review by Bauer et al(24) was published that continued on from Chang et al’s 
work. It sought to understand and quantify the impact of TB and was titled, “Systematic review and 
meta-analysis of the impact of tuberculosis on health-related quality of life.” (24)  The authors 
considered publications in which QoL was self-reported and quantitatively assessed, and compared 
patients with active and latent TB infection, those with ongoing respiratory symptoms after TB 
treatment and healthy controls. TB was considered broadly, regardless of whether classified as DS-TB 
or DR-TB. Their literature search was extensive in terms of databases and length of time (over fifty 
years), yet had dissimilar studies and literature compared to Chang et al, despite using the same or 
similar MeSH terms. The reviewers identified thirty-four different HRQoL and health utility instruments 
and noted that the most commonly used tool was the Short Form 36 Health Survey (SF-36).  
 
Twenty five percent of the studies that Bauer et al analysed used a longitudinal design and only one 
included MDR-TB patients (33% of cohort in Aydin et al’s study(72) and used the General Health 
Questionnaire 12 (GHQ 12)). Twenty-four studies conducted a quantitative assessment of HRQoL, three 
studies used up to four(55) tools, and most studies were cross-sectional. Bauer et al performed a quality 
rating on each cohort study according to the STROBE statement (which provided a checklist of items 
that should be included in observational studies(73)) and noted that assessment of HRQoL in TB 
patients was limited. (24)  Bauer et al granted that not including qualitative studies within their review 
(as it was beyond the scope of the study) omitted valuable insights for HCPs into patients’ experiences 
and needs in specific settings, and advised that further qualitative studies should supplement their 
quantitative information. Their review revealed that the greatest improvement in HRQoL occurred 
during the first 2-3 months of treatment in those patients with active TB and also concluded that MDR-
TB patients’ experiences probably differed substantially from those with DS-TB.  
 
Further work on QoL assessment in TB patients was done by Brown et al.. (69)  They evaluated the 
range of tools previously used, in their article entitled, “Health status and quality of life in 
tuberculosis,” published in 2015. They discussed thirty-two tools employed in QoL TB literature –
varying from general to disease or symptom-specific instruments. They acknowledged that different 
instruments evaluated different aspects of TB but noted that there were no tools designed specifically to 
assess QoL for TB patients per se, and in particular not for DR-TB patients. Brown et al concluded that 
QoL would be particularly impaired in MDR and XDR-TB due to a number of factors: “the complexity 
and duration of treatment, high rates of adverse events, additional stigmatisation, difficulties with family 
life, fertility and employment” (69)  - ear-marking these patients for urgent assessments of QoL 
especially when undergoing treatment. This would suggest that a specific DR-TB QoL assessment tool 
be required. 
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Having reviewed a large number of QoL tools, Brown et al commented that it was impossible to 
calculate a single numerical value that represented the impact of TB on an individual and they tabulated 
what the ideal TB QoL instrument would look like. (69)  This was informative in the development of the 
questionnaire utilised in this research study. Chapter 3 discusses this further. 
 
Both Bauer and Brown mentioned the DR-12 instrument used in Dhingra’s study (“Health related 
quality of life (HRQL) scoring (DR-12 score) in tuberculosis – additional evaluative tool under 
DOTS”). (74)  DR-12 was purportedly a TB-specific QoL instrument comprising two domains: 
symptoms and socio-psychological and exercise adaptation. However, Guo et al in “Measuring health-
related quality of life in tuberculosis: a systematic review”, (75)  questioned the methods used by 
Dhingra to claim strong construct validity of this instrument and pointed out weak statistical analysis. 
 
The researcher found one English article relating specifically to QoL in DR-TB: “Quality of life of Multi 
Drug Resistant Tuberculosis Patients: a Study of North India,” (70)  published in Acta Medica Iranica 
in 2014 by Sharma et al..Theirs claimed to have been the first study to compare QoL of MDR-TB and 
PTB (taken to mean DS-TB) – and the first the researcher found that compared QoL to a control group. 
However, the article did not mention the socio-demographics of the control group nor the number of 
control participants. They recruited both PTB(50%) and MDR-TB(50%) patients, and interviewed 
outpatients at a tertiary hospital using the WHOWOL BREF scale (Abbreviated version of the  
World Health Organization Quality of life -100 Assessment tool). Inclusion criteria were unclear but 
alluded to newly diagnosed patients being excluded.  
 
They found that the QoL of MDR-TB patients was lower than DS-TB and controls, and that all domains 
of QoL were affected - psychological, social and environmental (which related to physical safety and 
financial security). Sharma et al advised that a valid, TB-specific QoL instrument be designed, but did 
not elaborate on the reasons for the WHOWOL BREF scale being inadequate. This was a culturally 
representative study of Northern India that mentioned: “lakhs” (a measurement of a thousand people), 
difficulty arranging marriages for TB sufferers, and that MDR-TB patients were required to fund their 
own treatment. Most of the cited references were studies from lower socio-economic countries – India, 
Pakistan, Honduras and Vietnam. 
 
Mention must be made of Ahmad et al.’s prospective study, “Effects of Multidrug Resistant 
Tuberculosis Treatment on Patients’ Health Related Quality of Life: Results from a follow up 
study”,(64) published in 2016. They focused on the treatment regimen’s impact on quality of life (as 
opposed to the DR-TB infection per se). They recruited MDR-TB patients at a TB hospital serving a 
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large province in Pakistan, and had participants self-complete the Urdu version of the SF-36 at their 
baseline visit, at 12 months and at completion of treatment. It was unclear whether patients required 
admission to hospital at baseline for initiation of treatment (given that the data was collected in 2012-
2013) and the absence of a control group of Pakistani DS-TB patients. Instead, United States general 
population norms were used as per the scoring software, which was a shortcoming of the study.  
 
Considering Brown et al’s “ideal” QoL study features(69) – Ahmad et al collected meaningful data in 
their longitudinal, prospective study that reported to Pakistani and global National Tuberculosis 
Program (NTP) managers that (a) despite the improvement of patients’ HRQoL when on MDR-TB 
treatment, study participants still had a poor HRQoL and residual impairment at the end of TB 
treatment, and (b) during treatment, many MDR-TB patients were susceptible to depression.(64) 
 
There was an underlying sentiment in the literature that QoL instruments be culturally representative 
and developed using population groups with similar cultural and socio-demographic backgrounds to the 
average TB patient. (75)   
  
2.6   Symptom burden in DR-TB patients 
A local study, Senthilingam et al’s “Lifestyle, attitudes and needs of uncured XDR-TB patients living in 
the communities of South Africa: a qualitative study”, (35)  published in 2015, was reviewed. In this 
study, XDR-TB patients not on treatment in the community and irrespective of their HIV status, were 
interviewed telephonically (to negate infection risk). The posed questions explored their daily lives - pre 
and post infection with TB, the impact of the disease, life in hospital and after release, and thoughts of 
their future. These questions would be deemed “culturally sensitive” - which is discussed later. The 
study’s objective was to ascertain improved models of care and identify potential routes of transmission. 
The study’s shortfalls were the telephonic interview format, the small number of patients interviewed 
(twelve), the interview not being in respondents’ first language and small representations of black (25%) 
and female (17%) patients in the study (compared to the cohort characteristics - 57% and 42% 
respectively).  
 
Having thematically analysed the nine patients’ and three family members’ answers, Senthilingam et al 
found that patients’ were concerned about the futility of treatment regimens and financial subsistence; 
and expressed mistrust of HCPs and a need for purpose in life. (35)  Their findings affirmed that the 
needs of uncured XDR-TB patients, not on treatment, were not being met within the current model of 
care in the Western Cape and advocated for community-based palliative care support. 
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Thomas et al’s “Psycho-Socio-Economic Issues Challenging Multidrug Resistant Tuberculosis Patients: 
A Systematic Review”, (22)  published in 2016, gave insight on further issues affecting MDR-TB 
patients. This review, however, omitted valuable keywords in their original search criteria (such as 
“economic”, “quality of life”, “financial” and “spiritual” – the last two being TB-specific QoL domains 
described by Chang), which would have made the search more comprehensive. They mentioned that 
60% of the global burden of MDR-TB disease was borne by China, India and Russia; yet, only 3 of the 
15 studies reviewed were conducted in one of those countries (India) – the reasons for which were 
presumably due to language of publication or scarcity of research. Two of the three were part of an 
HIV/MDR-TB interventional study and one study was from rural South Africa. Two of the studies 
related to patients with concomitant MDR-TB and HIV, which found that HIV amplified the already 
severe psychosocial burden faced by MDR-TB patients. (46,76)  Studies relating to the pharmacology of 
MDR-TB medications were excluded – which might have yielded further valuable information 
regarding adverse psychological or psychiatric drug side effects. The 15 chosen articles varied in their 
methodologies and did not permit formal meta-analysis. The narrative approach using “thematic 
synthesis” effectively reflected the MDR-TB patients’ psychological and socio-economic experiences. 
The descriptive themes were organised into three sub-sections: (a) Psychological issues (b) Social issues 
and (c) Psychosocial intervention studies. Further analysis assessed the relationship between 
psychosocial intervention and MDR-TB outcomes (which was not the primary objective of the 
systematic review).  
 
The authors concluded that there was a dire need for “feasible, innovative psychosocial and economic 
intervention studies” (22)  that would enable DR-TB patients to better cope with their diagnosis and 
improve their QoL. This resonated with the urgent appeal for palliative care intervention.  
 
Further literature was sought for the high-burden countries Russia and China using “MDR-TB”, “drug-
resistant TB”, “quality of life”, “Russia” and “China” on the databases mentioned previously – but were 
unsuccessful. India was not well represented in the previous systematic review, therefore literature that 
pertained to their psychosocial issues of DR-TB patients was sought, specifically using the EBSCO 
database platform as well as searching The Indian Journal of Tuberculosis.  
 
An article worth mentioning is Venkatraju and Prasad’s, “Psychosocial trauma of diagnosis: a 
Qualitative study on rural TB patients’ experiences in Nalgonda district, Andhra Pradesh”. (20)  The 
authors’ intentions were to address TB patients’ psychosocial needs, having recognised that India’s 
existing control strategy largely ignored the human and social aspect of care. (20)  In this study, 110 
purposively recruited, recently diagnosed TB patients (type not specified) in two rural clinics were 
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interviewed using a semi-structured format and asked what the single most troublesome psychosocial 
issue was that they experienced upon being informed they had TB. Venkatraju et al described the 
diagnosis as being traumatic in their title. 
 
A limitation noted in this study was that the questions seemed misinterpreted by some respondents and a 
pilot study would have been beneficial to test the acceptability of the question. Interviews were also 
conducted in the respondent’s first language, translated into English, (the reliability of the translation 
was not mentioned), and then analysed, which might not have preserved the original connotations and 
meaning of the answers.(77) 
 
Qualitative content analysis showed that 37.3% of respondents experienced worry/depression, 23.6% 
disbelief/shock, 16.4% embarrassment/shame, 12.7% a fear of death, 9.1% fate and 0.9% relief when 
given the diagnosis of TB. These significant findings affirmed the Declaration on Palliative Care and 
MDR/XDR-TB(37): that palliative care be integrated from the time of diagnosis. 
 
Venkatraju and Prasad recommended that TB management be “culturally sensitive” to meet the patients’ 
psychosocial needs. (20,78)   
 
2.7   Cultural competency 
Two proponents of cultural competency and sensitivity in the literature were Epner(79) and 
Papadopoulos. (80)  Epner described “culturally competent” clinical practice as being patient-centred, 
with awareness of socio-cultural issues and health beliefs important to the patient and their community. 
(79)  Communication skills were recognised as paramount – particularly asking the patient what 
mattered most to them in their experience of illness and treatment.(79) A similar question was asked in 
the research questionnaire. 
 
Papadopoulos defined “culturally competent” compassion as the ability to understand another’s 
suffering and to intervene in a culturally appropriate and acceptable manner. (80)  Such a HCP would 
not only focus on the disease and its treatment, but would also be aware of patients’ psychosocial 
suffering, consider the patients’ fears about the illness and its impact on their physical and psychosocial 
functioning. (20)   
 
2.8    Functional status of DR-TB patients 
Chang et al’s(63) systematic review did not identify any studies that examined the impact of TB disease 
symptoms on physical functioning (that is their the ability to perform basic activities of daily living). 
 30 
Further searches in the literature found Godoy et al’s, “The functional assessment of Patients with 
Pulmonary Multidrug-Resistant Tuberculosis”,(65) published in 2012.  In this study, MDR-TB patients, 
after 18 months of treatment, were assessed to determine their respiratory function, functional capacity 
and QoL. Patients with co-morbidities affecting respiratory function were excluded. They found that 
78% of their sample patients had impaired respiratory function (as assessed by formal physician-
conducted pulmonary function tests and 6-minute walking test) and 78% of their sample patients 
reported impairment in QoL (as assessed by Airways Questionnaire 20). They stated that the ventilatory 
impairments impacted the functionality of the MDR-TB patients and suggested that MDR-TB patients 
post-treatment required continued intervention measures to help improve their QoL. 
 
To measure functional status in pulmonary TB patients, de Vallière and Barker used a modified ECOG 
score and looked at the association between poor performance status and early death in patients with 
pulmonary tuberculosis. (68)  The objective of the study was to determine whether the performance 
status of pulmonary TB patients at the initiation of anti-TB treatment was associated with death within 
two months. (68)  This South African study was done in the Limpopo province in 2005. From their data, 
the Kaplan Meier survival curves showed an increased risk of dying with poorer performance status – 
greatest with performance scores of 3 or 4. (68)  They commented that they were unable to identify a 
scoring system that evaluated TB patients’ morbidity.(68) 
 
2.9   Causes of death among DR-TB patients 
Van der Walt et al, in 2016, noted the global scarcity of data relating to causes of death among DR-TB 
patients, regardless of their HIV status, both during and after treatment. (67)  In 2011, Waitt and 
Squire’s systematic review of risk factors for death in patients started on TB treatment, found that in 
high HIV/TB regions: HIV co-infection, atypical chest x-ray features, sputum smear-negative disease, 
advanced immunosuppression and malnutrition were risk factors. (81,82)  In low HIV/TB burden 
regions the risk factors included increased age, typical features of severe TB on chest x-ray, smear 
positivity and socio-demographic disadvantage. (81,82)   
 
A Cape Town study, led by Osman et al undertook a retrospective analysis of all adult deaths during TB 
treatment in the city between 2009 and 2012 to identify risk factors for mortality in relation to HIV 
infection.(81) This analysis did not include DR-TB patients and relied upon the accurate reporting of 
death at the primary health care clinic in a paper-based register. Their patient data was stratified 
according to HIV status and Kaplan Meier curves were generated for the time of death after starting TB 
treatment. Robust statistical modelling determined which demographic and clinical characteristics were 
linked to death. Osman et al found that independent risk factors for death were: being male, HIV-
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positivity, being 65 years and older, having extra-pulmonary TB, or retreatment cases.(81) They 
mentioned culturally relevant factors that impacted mortality of patients in Cape Town such as alcohol 
dependence, cigarette smoking, diabetes, malnutrition and mental ill health. For those TB patients who 
were HIV co-infected: greater immunosupression, poor ARV uptake and opportunistic infections meant 
worse outcomes. 
 
Osman et al’s study did not include DR-TB patients, but their methodology could be replicated for DR-
TB patients, with the inclusion of DR-TB defaulters and those whose treatment had failed or had been 
withdrawn. 
 
2.10 The Hypothesis 
The literature alluded to quality of life and symptom burden being linked by functional status. Ahmad et 
al’s study stated that the functional impairment of patients was indicative of their HRQoL. (64)  In 
another study, “Factors associated with lower quality of life among patients receiving palliative care”, 
Chui et al found that patients with less severe physical symptoms had better functional status and QoL. 
(83)  Similarly, a single debilitating physical symptom would likely impact their physical functioning 
status and in turn patients’ QoL. (83)  Justice et al’s study (which related to HIV infection) maintained 
that effective symptom management improved the patient’s QoL by reducing the burden of symptoms 
experienced. (84)  Therefore, quality of life, symptom burden and functional status are linked. The 
implication in this research study would be that the worse the physical symptoms (or symptom burden), 
the worse the functional status (or ECOG score(85)) - the worse the quality of life (or APCA-POS 
score). The Supportive and Palliative Care Indicators Tool (SPICT) identified poor performance status 
as an indicator of deteriorating health,(86) and Gestsdottir et al claimed that worsening functional status 
was the single strongest indicator of deterioration and death.(87) That would imply that poor functional 
status was related to mortality – and palliative care need. This confirmed the researcher’s hypothesis that 
the lower the patient’s quality of life and the greater the symptom burden-the more the palliative care 
need of the patient. 
 
2.11 Conclusion 
The Literature review gave a framework for the development of the research questionnaire and disease 
trajectory (discussed in Chapter 5). It also helped validate the hypothesis proposed by the researcher that 
the lower the patient’s quality of life and greater the symptom burden-the more the palliative care need 
of the patient. The gaps noted in the literature corroborated the necessity of this research in the history 
of the Mycobacterium tuberculosis infection. It was emphasised in the literature review that evaluating 
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the quality of life, symptom burden, functional impairment and palliative care needs of DR-TB patients 
was important to the patient and their management strategies. Urgent strategies of care should be 
implemented that are effective, humane, and proportional to the needs of these vulnerable patients. 
(22,63,66)   
 































3.1   Introduction 
Chapter 3 discusses the planning and implementation of the research.  
 
3.2    Study design 
This study was an observational, quantitative and qualitative, cross-sectional cohort study.  
 
3.3   Study site 
The geographical location was the Southern sub-district of Cape Town. (The sub-districts of Cape Town 
were re-classified subsequent to the study completion.)  
 








3.4   Inclusion criteria for study 
▪ Patients infected with DR-TB (this included RMR-, RR-, MDR-, pre-XDR, XDR and TDR); 
regardless of whether their TB was pulmonary or extra-pulmonary. 
▪ They should be 18 years or older.  
▪ They should currently reside within the Southern sub-district of Cape Town.  
▪ The participants must be able to communicate in English, Afrikaans or Xhosa. 
▪ They must be able to give informed consent. 
 
3.5   Exclusion criteria for study  
▪ Those patients who had DS-TB, or DR-TB defaulters lost to follow-up.  
▪ Patients hospitalised at the time of data collection were not included.  
▪ Patients unable to communicate effectively.  
▪ Patients with diminished decision-making capacity (assessed as disorientated to time, place, or 
person). 
▪ Those patients currently incarcerated in Pollsmoor prison facility. 
 
3.6   Sample size 
The researcher generated a DR-TB patient list from the names provided by the City of Cape Town’s 
MDR-TB team and the names of patients known or attending the clinics in the southern sub-district.  
 
For completeness sake, the private pathology laboratory, Pathcare, was contacted to enquire about the 
prevalence of DR-TB isolates picked up in the private health sector. Pathcare tested 1162 patients in 
2016 in Cape Town - Rifampicin resistance was isolated in 234 patients, Isoniazid in 160, 
aminoglycosides in 20 and fluoroquinolones in 33. Pathcare, however, was unable to ring fence their 
data for the southern sub-district. (email correspondence with Pathcare’s J.Gerber on 13.06.2017, 
unreferenced) Patients diagnosed in private were referred to the local government clinics for ongoing 
management.  
 
On the 08.03.2017, the total number of DR-TB patients within the Southern sub-district of Cape Town 
on paper totalled 199. Figure 8 shows the proportions of patients at each clinic. This number of patients 
was further reduced after eliminating those patients fulfilling exclusion criteria and others that were 




                              Figure 8. Cohort of DR-TB patients on 08.03.2017  
 
Table 2. Cohort “ledger” 
Original 
number 




199       
 Age <18 9   190  
 DS-TB 1   189  
 MOTT/NTM 1   188  
 Incarcerated 6   182  
 Deceased 12   170  
 Hospitalized 20   150  
   Lost to follow up/defaulter 21 129  
   Treatment completed 3 126  
   Cured 13 113  
   Relocated 4 109  
   Discharged 16 93  
   Unknown to clinic 12 81  
   Lavender Hill clinic 22 59  
   Pilot study participants 6 53  
      28 (52.8%) 
 

































Unfortunately recruiting patients from the Lavender Hill clinic became too dangerous with road and 
clinic closures due to taxi and gangster violence.  
 
The number of possible patients was thus reduced to 53. The patients to be interviewed were then 
randomly chosen by convenience sampling, beginning at the clinics with the greatest number of DR-TB 
cases.  
 
3.7   Data collection tool 
An assessment tool specific to DR-TB patients’ palliative care needs was not identified in the literature. 
The researcher developed a multidimensional questionnaire for palliative care needs, by assessing the 
quality of life, functional status and symptom burden of DR-TB patients. The Literature Review in 
Chapter 2 discussed these variables in detail.  
 
The questionnaire was available in 3 languages:  English (Appendix 5), Afrikaans (Appendix 6) and 
Xhosa (Appendix 7). It was forward translated from English into Afrikaans and Xhosa by first-language 
translators, and then back translated into English to confirm the validity of the translation. Uniquely, the 
questionnaire did not require retrieval of information from the patient’s clinic file. 
 
Each participant was asked questions from a paper questionnaire that included five components:  
Table 3. Components of questionnaire 
 Tool 
Demographic details Individual questions (researcher-
designed) 
Functional Status ECOG score(85) 
Quality of life APCA African POS(88) 
Symptom burden Symptom checklist (researcher 
formatted) 
Personhood and dignity Modified Patient Dignity Question 
          
3.7.1   Demographic details [questions 1-26]: 
The demographic details of the participants provided information regarding age, socio-economic status, 
lifestyle habits, financial circumstances, home situation, previous TB, HIV co-infection, compliance and 
time of diagnosis and treatment initiation. These questions were designed by the researcher. Questions 
were answered by ticking a checkbox or by one-word answers. 
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3.7.2   The ECOG Scale of Performance Status [question 27]: 
The ECOG score measured the impact of DR-TB on the patient’s daily living abilities and measured 
their functional status. The ECOG classification consisted of six possible categories (scored 0-5) and 
was quick and easy to determine. This scoring system had been used in other studies of TB patients in 
South Africa. (68)  The APCA African POS guidelines also recommended using the ECOG score in 
conjunction with the APCA POS assessment. (89)   
 
3.7.3   The APCA African POS tool [questions 28-34]: 
The APCA African POS tool was chosen to be a QoL measure. It had been developed to assess a 
patient’s palliative care needs in terms of physical, psychological, social and spiritual concerns. (90)  It 
addressed patients’ optimal care requirements(89) and measured the quality of the care rendered with 
consecutive testing. As this research study was aimed at assessing the palliative care needs of the DR-
TB patients only, single use of the tool was performed and questions 8,9 and 10 of the original APCA 
African POS (that related to the patient’s family) were not included in this study. Single use had been 
discussed with the APCA African POS developers. 
 
This tool had been validated as a research tool applicable to the South African context (88) with the 
acknowledgment of the HPCA of South Africa and King’s College London in this regard. It was 
available in relevant translations (English, Afrikaans and Xhosa) for measuring the care outcomes of 
patients with life-threatening illnesses. (89)  Advantageously, the APCA-POS questions were short and 
easy to administer despite the respondent potentially being very weak or ill or residing in an informal 
settlement. (89)  The answers were scored using a 6-point Likert-type scale (from 0-5) and each score 
had corresponding descriptive labels and visual aid (Appendix 3). The researcher used a visual aid to 
complement the Likert scale and adjusted the recall period to one week instead of three days - which 
was permissible within the APCA African POS guideline stipulations.(89) Answers to questions 31-34 
were reversed as necessary when recorded (so that “0”= best and “5”= worst score throughout). 
 
3.7.4   Symptom list [questions 35-60]:  
Justice et al defined the objective of a symptom index: to identify and qualify symptoms representative 
of clinical phenomenon to advise effectively on intervention. (84)  A specific, validated DR-TB 
symptom checklist or scale was not found in the literature. (91)  As a result, the researcher identified the 
most burdensome symptoms of DR-TB in the literature(22,35,77,92,93) and together with input from 
local DR-TB experts compiled a list. These symptoms represented issues relating not only to the DR-TB 
disease, but also to common adverse drug reactions, associated DR-TB related stigma and economic 
 38 
burden. Financial and spiritual domains were included according to Chang et al’s recommendations. 
(63)  The content validity of the symptom burden list was discussed further with the researcher’s 
supervisor and experts within the DR-TB field.  
 
In order to minimise recall bias, study participants were asked to remember whether in the preceding 
week they had experienced each symptom from the checklist and asked to rate the symptom’s frequency 
and intensity using a visual Likert-type scale (see Appendix 4). 
  
3.7.5    Open-ended questions [questions 61 and 62]:  
These informal questions were added post pilot study - having considered Lopez et al.’s paper, 
“Knowing about you: eliciting dimensions of personhood within tuberculosis care”. (47)  The intent was 
to address the individual DR-TB patient’s priorities, uphold their dignity(47) and invite broader, more 
patient-centred concerns to be voiced. Question 62 was based on Chochinov’s Patient Dignity Question, 
(94)  and invited the respondent to “express their personhood” (47)  in a “culturally sensitive” (20)  
manner.  
 
3.8   Pilot study: 
The face validity and reliability of the questionnaire was verified by conducting a pilot study of six DR-
TB patients.  
 
The original questionnaire – which was entirely quantitative - insufficiently captured relevant, life-
changing issues for the pilot participants. Consequently, adjustments were made to a few questions and 
two qualitative open questions were added as discussed above.  
 
All those approached during piloting were willing to participate. Only one of the six pilot participants 
required urgent referral for further medical management. The clinic doctor was available for discussion 
and the formal distress protocol referral form was not required. This patient required eventual hospital 
admission for symptom management and sadly died soon after the pilot study was completed. Another 
patient interviewed in the pilot study died a few months after being interviewed. Due to the procedures 
put in place for confidentiality it was not possible to look back at their respective questionnaires and 
gauge the validity of their answers in predicting their unfortunate outcomes. 
 
The timing of the interviews coincided with their visit to the clinic. The length of time to explain the 
research, take consent and ask the questionnaire took between 20-27 minutes. Towards the end of the 
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interview, the participants seemed fatigued by the tedious verbal descriptions of the Likert-type scoring 
system and the visual scales were introduced to combat this as mentioned previously. 
 
A further pilot study was not deemed necessary once these comprehensive alterations were made. 
Supplementary ethics approval was received from the UCT Human Research Ethics Committee 
(HREC). These new or altered questions were forward and back translated as previously described. The 
pilot study patients’ answers were not included in the final data analysis.  
 
3.9   Palliative Care need allocation 
After finalising the content of the questionnaire, the researcher determined a score for each question that 
would rate as a “Palliative Care need”. This estimation was based on the literature review, other 
palliative care need assessment tools (SPICT(86), Gold Standards Framework(95)), clinical intuition, 
palliative care training and supervisory input. The consensus was that “Palliative Care need” be defined 
as:  
▪ ECOG score (q27) of 3 and above, 
▪ APCA African POS varied with each question (q28: score 2 and above; q29: 2 and above; q30: 3 
and above; q31: 2 and below; q32: 3 and below; q33: 2 and below; q34: 2 and below)  
▪ Symptom burden list - a score of 3 and above.  
 
This “need” allocation was not indicated on the paper copy of the questionnaire to ensure that no bias 
was introduced during the interview. 
 
3.10   Training of the researcher: 
The researcher ensured that she was equipped to answer any question regarding DR-TB that the study 
participants might have, and had a thorough understanding of each question and the scales used in 
answering. The APCA African POS training manual was referred to by the researcher and online 
support was accessed at www.pos_pal.org. 
 
Prior to the any contact with potential DR-TB study participants, the researcher was formally “fit-
tested” for an N95 mask* and the researcher ensured a sufficient supply of the requisite healthcare 
particulate respiratory and surgical masks. 
___________________________________________________________________________________ 
* 
An “N95 mask” is a disposable respiratory protective device  
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Before starting data collection, the researcher felt confident in undertaking the research. An additional 
research assistant was not utilised, however a Xhosa translator (available at the clinic) was required 
when interviewing Xhosa-speaking patients. In these instances, the researcher expressly instructed the 
translator to quote the questions verbatim from the Xhosa-translated questionnaire and to interpret 
directly back to the researcher avoiding extrapolation.  
 
3.11   Recruitment strategy   
The clinics with the highest incidence of DR-TB were targeted initially. The clinic managers were 
emailed requesting permission to visit the clinic and recruit DR-TB patients - with an attached copy of 
the research proposal, information sheet and HREC approval reference letter. The researcher also 
attempted to contact the clinic managers telephonically. However, several of the clinic’s email addresses 
and telephone numbers were out-dated, incorrect or went answered. After several attempts at contacting 
the various clinics and the clinic managers electronically and telephonically, the researcher attempted to 
meet the clinic manager on the day of visiting. Many times however, the researcher only had the 
opportunity to speak to the TB sister or sister-in-charge telephonically, getting the clinic manager’s 
permission by proxy from the TB sister. On the day of visiting the clinic, the researcher supplied the TB 
sister with a copy of the study’s information sheet with the researcher’s contact details, ethics approval 
and UCT HREC member’s contact details. 
 
The clinic TB sisters provided the researcher with information (telephonically or in person) regarding 
the number of DR-TB patients attending their clinics and the patients’ sputum conversion status, when 
patients were next due for a doctor’s appointment, support group or audiology appointment and times 
when best to visit the clinic (with respect to injection and medication dispensing times). DR-TB patients 
fulfilling the inclusion criteria were then approached at their respective clinics at these times.  
 
The researcher also liaised with the CCW/ DR-TB counsellor, and accompanied her on three occasions 
to known DR-TB patients’ homes. These patients had been informed of the research study and 
consented to participation prior to the researcher’s visit. 
 
The prospective study participants were informed of the study verbally and with the help of a printed 
Information sheet (see Appendices 8,9,10) that was theirs to keep. Patients were invited to ask 
questions, raise concerns or confer with family members regarding their participation in the study.  
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They were then invited to participate voluntarily and informed that there would be no monetary or other 
incentives offered for their participating. Patients were reassured that declining participation would not 
result in deleterious consequences. The researcher explained her non-involvement in their clinical 
management and was mindful to differentiate between patient’s routine standard of care to avoid any 
feeling of coercion. The distress protocol (see Appendix 20 and Section 3.16) was explained to the 
patient, and permission requested to refer by name to other HCPs should further management be 
necessary.  
 
After ensuring that the trial participant understood the purpose of the research study, how the 
questionnaire would be administered and how data would be collected, informed consent (Appendices 
11,12,13) with a witness’ signature was requested in order to continue.  
 
3.12   Data collection procedure  
Clinic activities and staff duties were not interrupted as a result of this study. In the clinic environment, 
patients were interviewed either in an unused office or outside garden; and in the home environment in 
an inside sitting area to ensure privacy. The researcher was responsible for explaining the research 
information sheet, taking informed consent and completing the questionnaires and took care to maintain 
confidentiality, dignity and respect for the participants during the interview process. This included when 
a Xhosa translator’s help was required. Before starting the questionnaire, the patient’s mental capacity 
and their understanding of confidentiality were determined by the researcher. 
 
Thereafter, the once-off interview proceeded, observing appropriate infection control measures - such as 
the use of particlate respiratory health masks, surgical masks, adequate ventilation and draft in interview 
area. The questions were asked in the order they appeared on the questionnaire, using visual aids to 
assist in answering the Likert-type questions and ensuring the researcher did not influence the 
participants’ responses.  
 
The participants’ comments and answers were recorded on the questionnaire verbatim by the researcher. 
The researcher carefully documented anecdotal narrative data offered by the participants of their 
personal accounts during the interview in a non-biased way. Other additional information regarding the 
interview – such as the use of facemasks, the trial participant’s emotional display, those present during 
the interview were also written down.  
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If the participant required further urgent management (deemed a “Palliative care Referral”), with their 
permission, the participant was referred back to the clinic doctor with a referral letter detailing the issues 
and concerns that arose during the interview (see Appendix 14). If the doctor was not available 
immediately, either the TB-sister was informed and the referral letter was placed in the patient’s file, or 
the CCW/DR-TB counsellor was informed to ensure the patient be seen by the doctor as soon as 
possible.  
 
The interview concluded by thanking the participant for their time and willingness to participate, and by 
reiterating that they keep the information sheet in a safe place and contact the researcher should there be 
any queries.  
 
3.13   Data storage & confidentiality   
The data was extracted from the questionnaire by the researcher only, in a private secure location, as 
soon after the interview as feasible. The raw data was loaded onto a password-protected computer and a 
cloud service was used as backup. Confidentiality was maintained by storing the questionnaire and 
informed consent documents in separate sealed files with no means of associating names to answers. 
These folders were not misplaced at any stage and were not handled by a third party. The participant’s 
name was ticked off the compilation list to prevent duplication. 
 
Paper copies of the completed questionnaire were locked in a secure storage facility - with access 
available to the researcher only. The study participant’s data will be retained until the publishing of a 
peer-reviewed journal article. The clinical investigator takes responsibility for the storage, access and 
final disposal of the raw data (including data from the pilot study). This collected data will not be shared 
with other parties. 
 
3.14   Data analysis  
3.14.1   Quantitative data analysis 
Quantitative data was entered into a bespoke Excel spreadsheet by the researcher. Statistical guidance 
was provided by Mr Jordache Ramjith, Lecturer and Biostatistician in the Division of Biostatistics and 
Epidemiology at the UCT School of Public Health and Family Medicine. 
 
Basic statistical analysis was undertaken, such as descriptive statistics and cross-tabulation. Descriptive 
statistics was used to explain the study participants’ demographic profiles. Mann-Whitney tests were 
performed to compare two independent variables and statistical significance determined. Pie charts and 
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bar graphs were used to represent the data visually. The ranking, frequency, percentage, prevalence and 
severity of symptoms were tabulated. Spearman’s Rank Correlation compared variables to consider 
statistical significance. The mean total of symptoms and a summative measure of functional status was 
calculated. Cronbach’s alpha analysis was used to analyse the reliability of the questionnaire, 
consistency and insightfulness of patients’ answers – particularly with regards to psychosocial concerns. 
A Cronbach’s alpha score of >=0.70 was considered to indicate satisfactory reliability of the scale.(69) 
  
As mentioned previously, “Palliative Care need” was defined in each question according to a researcher-
determined rating on the Likert scale. Proportions of people in need of palliative care according to their 
quality of life and symptom burden were determined with a confidence level of 95%. A probability 
below 0.05 was regarded as being statistically significant. Multiple Logistic regression was carried out 
to determine how quality of life, functional status and symptom burden affected Palliative Care Referral.   
 
Results of the data analysis are presented in Chapter 4. 
 
3.14.2   Qualitative Content analysis 
Each interview was read and then re-read and all additional comments, context and descriptions given 
by the participants and impressions of the researcher were transcribed into the researcher’s notes. This 
narrative data was included along with the open-ended questions (q61 and q62) in the content analysis. 
 
Initially the qualitative analysis focused on how participants responded to each question and 
consistencies and differences were identified. Later, connections and relationships between questions 
were explored. Information was categorised according to themes and organised into coherent categories. 
 
3.15   Ethical considerations   
This study was researcher-funded and undertaken to fulfil requirements for the UCT Masters of 
Philosophy in Palliative Medicine. The research proposal was initially submitted to the UCT HREC for 
ethics approval on 25.05.2016 (reference REC 7743). After deliberation, the HREC requested 
clarification on a number of issues. These were sufficiently addressed with modifications to the study 
and full ethics approval was later granted on 12.10.2016. Further ethics approval was received from the 
HPCA (Appendix 15), and permission granted to undertake research at the clinics managed by the 
Department of Health (Appendix 16) and City of Cape Town (Appendix 17) in the southern sub-district. 
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After the completion of the pilot study, the title, inclusion and exclusion criteria were amended and the 
research proposal was submitted again to UCT HREC on 27.02.2017. DR-TB patients admitted to 
hospice or hospital were excluded and HPCA was later notified that further ethics approval would not be 
pursued. Full ethics approval from UCT HREC was received on 08.03.2017 (See Appendix 19). The 
Department of Health and City of Cape Town were informed.  
 
DR-TB patients might have been vulnerable if acutely unwell, had a short life expectancy, were 
experiencing stigmatisation or lived in dangerous, impoverished socio-economic conditions. 
Additionally, trial participants might have been unemployed, have hearing impairment due to ototoxic 
anti-tuberculosis drugs, may find communicating difficult due to the necessity for wearing protective 
masks or have a low level of education and literacy. The researcher acknowledged and factored these in 
to the culturally sensitive manner in which patients were approached, explained informed consent and 
interviewed. Confidentiality was maintained throughout and patients’ rights and welfare were protected.  
 
It was the researcher’s opinion that the benefits of the research to ascertain their palliative care needs 
outweighed the potential risks – however unrealistic expectations of benefits from participation or future 
palliative care services required further explanation where necessary. 
 
3.16   Distress protocol 
This safeguard was mentioned to the patient prior to their consenting to participate in the study. The 
patient was reassured that should they display or express physical or psychological distress during the 
questionnaire, then they could pause the questioning and either abandon or restart (with a rescheduled 
appointment time and date) the interview when they felt more able. (89)  Appendix 20 detailed this 
procedure.  
 
The protocol stated that should the distress warrant referral for further management, the researcher 
would then make arrangements to refer the patient to the appropriate personnel at the local clinic. A 
referral form (Appendix 14) with the patient’s name, the study’s name and the clinical investigators 
details were included. Importantly, the protocol also stated that should the participant need to terminate 
the questionnaire, their further care or management would not be deleteriously affected. 
 
Of equal importance, the protocol stated that should the researcher feel that her physical safety be in 
jeopardy or that infection control be insufficient, that the questionnaire be halted, and that steps 
described in the distress protocol be followed.  
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The study design and recruitment of the DR-TB patients in the southern sub-district of Cape Town has 
been detailed, with distress protocol and ethical considerations emphasised. The next chapter documents 



































Results of the study 
___________________________________________________________________________________ 
4.1   Introduction 
Chapter 4 presents the results of the 28 participants’ answers that were collected from 24.03.2017 until 
16.08.2017 (excluding April and July school holidays). These participants represented DR-TB patients 
at various stages of their illness trajectory, attending clinics within the Southern sub-district of Cape 
Town. The small sample size was a limitation of the study. 
 
The data is presented in the same order as the questionnaire. Each answer has frequencies and 
percentages alongside, and graphs and charts have been added to provide a clearer visual representation 
for interpretation. Patients’ quotes have been italicised and the English translation given in brackets 
where necessary. 
 
4.2   Cohort 
The table below summarises the cohort characteristics. 
 
Table 4. Data collection and sample details 
Number of subjects eligible from the target population: 53 
Number of those approached and invited to participate:  29 
Number recruited from those approached:  29 
Number of those evaluated from recruited:  28 
Number of those evaluations included in the analysis:  28 
Number of people where an appointment was made for an alternative time: 1 
Number of interviews where a Xhosa translator was required:  4 
Number of interviews discontinued - This patient had schizophrenia and lacked mental capacity to answer 
questions consistently and appropriately. 
1 
The number of patients who wore their mask during the interview (surgical or tissue):  26 
The number of times the researcher wore her mask during the 29 interviews:  29 
 
Due to this study being descriptive, a sample size calculator was not appropriate, having discussed the 
sample size estimation with the UCT Biostatistician. Recruitment of patients was discontinued after 28 
patients were interviewed due to data saturation, but safety concerns, time and resource constraints also 
contributed. 
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4.3   Palliative Care need assessment 
In the table below, the number of participants’ answers falling within the“palliative care need" range for 
each question have been highlighted. Section 3.9 on page 39 detailed the researcher-defined “palliative 
care need” scores for each question. The total number of respondents that had a palliative care need for 
each question are found in the far right column. 
 
Table 5. Number of respondents scoring within the “palliative care need” range in each question 
Question/Score 0  1  2  3  4  5  Total (%)          
Q27    3 0 0     3 (10.7) 
Q28   6 2 2 3  13  (46.4) 
Q29   5 2 2 5  14  (50.0) 
Q30    0 2 7    9  (32.1) 
Q31    3 0 5    8  (28.6) 
Q32   5 1 1 5  12  (42.9) 
Q33    4 2 3    9  (32.1) 
Q34    2 2 4    8  (28.6) 
Q35    2 4                       6  (21.4) 
Q36    0 4                        4 (14.3) 
Q37    5 5                     10  (35.7) 
Q38    0 4                       4  (14.3) 
Q39    3 4                       7  (25.0) 
Q40    0 2                         2  (7.1) 
Q41    1 3                       4  (14.3) 
Q42    3 7                     10  (35.7) 
Q43    0 0                            0  (0) 
Q44    3 4                       7  (25.0) 
Q45    3 2                       5  (17.9) 
Q46    3 9                     12  (42.9) 
Q47    0 2                         2  (7.1) 
Q48    2 3                       5  (17.9) 
Q49    0 2                         2  (7.1) 
Q50    4 5                        9 (32.1) 
Q51    0 1                          1 (3.6) 
Q52    4 5                        9 (32.1) 
Q53    2 5                        7 (25.0) 
Q54    2 5                        7 (25.0) 
Q55    1 3                        4 (14.3) 
Q56    0 5                        5 (17.9) 
Q57    1 2                        3 (10.7) 
Q58    3 0                        3 (10.7) 
Q59    2 6                        8 (28.6) 
Q60    2 19                         21 (75) 
 
Furthermore, “Palliative Care need” was also determined for each study participant. The number of 
times a participant had an answer within the pre-determined palliative care range (or shaded area in 
above table), a score of “1” was given, and outside the range a score of “0”. These binary scores were 
totalled for individual respondents and have been represented in the following figure. All participants 
had at least one answer within the shaded area – therefore all had a specific palliative care need. The 
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graph indicated that all those participants with a score of 10 or more required urgent palliative care 
referral on the day of their interview. 
 
Figure 9. The “Palliative care needs” scores for individual respondents (n=28) 
Range of scores: 1 to 23. (Red highlighted scores: respondents referred urgently) 
 
 
4.4   Demographic details  
 
Table 6. Answers to questions 1 to 9  
Questions 
1. Age (years): Youngest: 18 Oldest: 63  Median: 42 
2. Sex: (n; %) Male: 13 (46.4%) Female: 15 (53.6%) 
3. Citizen: (n; %) South African: 27 (96.%) Non-South African: 1 (3.6%) 
4. Lang: (n; %) Afr: 11(39.3%) English: 6 (21.4%) Xhosa: 8 (28.6%) Other: 3 (10.7%) 












Other: 0 (0%) 
6. Ed lvl:(n; %) Prim: 13 (46.4%) S’dary: 13 (46.4%) Tertiary: 0 (0%) None: 2 (7.1%) 
7. Setting: (n; %)  Clinic: 25 (89.3%) Household: 3 (10.7%) 
8. Dwell: (n; %) Brick house: 13 (46.4%) Informal settlement: 15 (53.6%) 
9. No. of windows  Least: 0  Max: 10 Mode: 3 
 
Age categories (such as those used in de Vallière and Barker’s study(68)) were compared with ECOG 
and median APCA-POS and Symptom burden scores and statistical significance determined. The 
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Table 7. Age categories versus median ECOG, APCA-POS and Symptom burden scores 
 
 Median ECOG  Median APCA-POS  (IQR) Med. Symptom burden (IQR) 
Age 35-49 yrs (n=14) 1 12.5 (11) 27 (39.5) 
Other age  (n=14) 1 9 (7.75) 24 (24.5) 
Median difference 0 3.5 3 
 
 
Mann-Whitney test of median APCA POS score: age (35-49 years) vs other age (using online statistical 
analysis site: www.socscistatistics.com/tests/mannwhitney) (96) : 
The p-value is 0.20766. The result is not significant at p > 0.05. 
 
Mann-Whitney test of median Symptom burden score: age (35-49 years) vs other age (using online 
statistical analysis site: www.socscistatistics.com/tests/mannwhitney)(96) 
The p-value is 0.4593. The result is not significant at p > 0.05. 
 
The Mann-Whitney test is a non-parametric test to compare outcomes between two independent groups. 
(96)   
 
This analysis showed that palliative outcome and symptom burden scores were not influenced by age. 
 
“Palliative Care need” of the 35-49 year age group is indicated in Figure 10. 
 
Figure 10. The “Palliative care needs” scores for individual respondents (n=28).  
(Red highlighted scores: respondents referred urgently. Black dots: respondents 35-49 years)  
 
Male and female responses were compared with median APCA-POS and median Symptom burden 
scores: 
Table 8. Sex versus median APCA-POS and median Symptom burden score 
 
 Median APCA-POS score (IQR) Median Symptom burden score (IQR) 
Male (n=13) 11 (8) 22 (21) 
Female (n=15) 11 (13) 41 (40) 
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Mann-Whitney test of median APCA-POS score male vs female respondents (using online statistical 
analysis site: www.socscistatistics.com/tests/mannwhitney) (96) : 
The p-value is 0.85716. The result is not significant at p > 0.05. 
 
Mann-Whitney test of median Symptom burden score of male vs female respondents (using online 
statistical analysis site: www.socscistatistics.com/tests/mannwhitney) (96) : 
The p-value is 0.101. The result is not significant at p >0.05. 
 
Thus, the sex of the patient did not influence their APCA-POS or symptom burden scores. 
 
Figure 11. The “Palliative care needs” scores for individual respondents (n=28) 
(Red highlighted scores: respondents referred urgently. Orange data points: Male patients)  
 
 
Question 10. Suburbs where participants resided 
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Capricorn:5 Grassy Park:1
Heathfield: 1 Hout Bay: 3
Lavender Hill: 1 Lotus River:1
Masi 4 Ottery: 1
Overcome Heights: 1 Plumstead 1
Parkwood 3 Rocklands 1
Seawinds: 3 Strandfontein 1
Westlake:2
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Demographic details continued 
 
Table 9. Answers to questions 11-26 
Questions 
11. No. of people in household: Most: 10 Mode: 4 
12. Others with TB at home: n (%) Yes: 7 (25%) No: 21 (75%) 
13. Previously had TB: n (%) Yes: 18 (64.3%) No: 10 (35.7%) Uncertain: 0 (0%) 




























16. Currently taking meds: n (%) Yes: 25 (89.3%) No: 3 (10.3%) 






Sputum positive:  
3 (10.7%) 
18. HIV status: n (%) Pos: 16(57.1%) Neg:12(42.9%) Unwilling: 0 (0%) Unknown: 0 (0%) 
19. On ARVs: n (%) Yes: 15 (53.6%) No: 13 (46.4%) 
20. No. of tablets: n (%) <10: 3 (10.7%)  
[0 tabs:1 (3.6%) 
10-19: 7 (25%) >20: 18 (64.3%) 
21. Problems taking meds: n (%) Yes: 18 (64.3%) No: 10 (35.7%) 
22. Smoke cigarettes: n (%) Yes: 14 (50%) No: 14 (50%) 
23. Using other drugs: n (%) Yes: 2 (7.1%) No: 26 (92.9%) 
24. Hospitalised in last year: n (%) Yes: 15 (53.6%) No: 13 (46.4%) 
25. HBC help: n (%) Yes: 5 (17.9%) No: 23 (82.1%) 
26. DR-TB affected work: n (%) Yes: 18 (64.3%) No: 8 (28.6%) N/A: 2 (7.1%) 
 
HIV status was compared with median APCA-POS, ECOG and Symptom burden scores. 
 
Table 10. HIV status versus median APCA-POS, median ECOG and median symptom burden scores. 
 
 Median APCA-POS (IQR) Median ECOG (IQR) Median Symptom burden (IQR) 
HIV positive: 12.5 (11.5) 1 (1) 23.5 (33.25) 
HIV negative: 11 (1) 1 (1.25) 25 (7.5) 








Figure 13. The “Palliative care needs” scores. Red highlight: urgent referrals. Purple data point: HIV-positive pts 
 
 
            Figure 14. One patient’s daily pill requirement 
  
 
Patients who experienced problems with pill taking were compared to the number of pills prescribed.  
Table 11. Contingency table showing “problems with taking tablets” vs “number of tablets required” 
 <10 tabs 10-19 tabs >20 tabs 
Problems-Yes n (%) 1 (3.6%) 5 (17.9%) 12 (42.9%) 
Problems-No n (%) 2 (7.1%) 2 (7.1%) 6 (21.4%) 
 
The Contingency table below compared patients who reported DR-TB affecting their work with median 
APCA-POS and symptom burden scores. 
Table 12. Work affected versus median APCA POS and median Symptom burden scores 
 Median APCA African POS score Median Symptom burden score 
Affected work-Yes 12.5 36.5 
Affected work-No 9.5 19 
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4.5   Functional status (ECOG score):  
 
Table 13. Definition of ECOG scoring system(85) with prevalence in current study 
ECOG score n  (%) 
0 Fully active: able to carry on all activities without restriction 8 (28.6) 
1 Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or 
sedentary nature 
10 (35.7) 
2 Ambulatory and capable of self-care but unable to carry out any work activities. Up and about more 
than 50% of waking hours 
7 (25) 
3 Capable of only limited self-care: confined to bed or chair 50% or more of waking hours 3 (10.7) 
4 Completely disabled: cannot carry on any self-care: totally confined to bed or chair 0  
5 Dead 0 
 
The table below compared the ECOG scores with the median APCA-POS and symptom burden scores. 
 
Table 14. ECOG scores versus median APCA-POS and median symptom burden scores 
ECOG score Median APCA-POS score (IQR) Median Symptom burden score (IQR) 
0 11 (9.25) 14.5 (16) 
1 7.5 (6.25) 23 (31.25) 
2 22 (13.5) 41 (30.5) 
3 11 (2) 27 (10.5) 
4 / / 
5 / / 
 
4.6   APCA African POS score  
Answers to questions 31-34 were reversed as necessary when recorded (so that “0”= best and “5”= worst 
score throughout). 
 
Question 28: Please rate your pain during the last week 
Question 29: Have any other symptoms been affecting how you feel in the last week? 
Question 30: Have you been feeling worried about your illness in the past week? 
Question 31: Over the past week, have you been able to share how you are feeling with your family and friends? 
Question 32: Over the past week have you felt that life was worthwhile? 
Question 33: Over the past week, have you felt at peace?  







Table 15. APCA-POS scores 
 
APCA-POS score Q28 n (%) Q29 n (%) Q30 n (%) Q31 n (%) Q32 n (%) Q33 n (%) Q34 n (%) 
0 12 (42.9) 3 (10.7) 12 (42.9) 19 (67.9) 13 (46.4) 8 (28.6) 18 (64.3) 
1 3 (10.7) 3 (10.7) 3 (10.7) 0 (0) 3 (10.7) 3 (10.7) 2 (7.1) 
2 6 (21.4) 7 (25) 4 (14.3) 1 (3.6) 5 (17.9) 7 (25) 0 (0) 
3 2 (7.1) 5 (17.9) 0 (0) 3 (10.7) 1 (3.6) 4 (14.3) 2 (7.1) 
4 2 (7.1) 2 (7.1) 2 (7.1) 0 (0) 1 (3.6) 3 (10.7) 2 (7.1) 
5 3 (10.7) 5 (17.9) 7 (25) 5 (17.9) 5 (17.9) 3 (10.7) 4 (14.3) 
 
The scores of those patients who had described experiencing pain were compared to those not 
describing pain in terms of their ECOG, median APCA-POS, median symptom burden scores and need 
for referral. 
 
Table 16. Contingency table comparing “No pain” to “pain” scores 
 
 Median APCA-POS (IQR) Mode ECOG  Median symptom burden 
(IQR) 
Urgent referral  
n (%) 
No Pain (score 0) n=12 6.5(12.75) 0 12(17.5) 3(25) 
Pain (score 1-5) n=16 11(6) 2 34.5(26) 11(68.8) 
 
Mann-Whitney test comparing median APCA-POS (pain vs no pain):  p-value is 0.09894. The result is 
not significant at p > 0.05. 
 
Mann-Whitney test comparing mode ECOG (pain vs no pain): The p-value is 0.00804. The result is 
significant at p < 0.05. 
 
Mann-Whitney test comparing median Symptom burden (pain vs no pain). The p-value is 0.02034. The 
result is significant at p < 0.05. (using online statistical analysis site: 
www.socscistatistics.com/tests/mannwhitney) (96) 
 







The symptoms that patients mentioned in question 29 were: 
Figure 15. Prevalence of “other” symptoms 
 
 
Respondents’ total APCA African POS scores were calculated and are depicted in the figure below 
(keeping in mind that for q31 to 34 the scores were reversed). Therefore the best possible total score 
would be zero, and the worst possible total score 35. The blue line indicated the median score of 11. 
   Figure 16. Total APCA African POS scores  
 
                      
4.7   Symptom list 
Questions 35 to 60 had been rated according to the following Likert-type scale: 
Table 17. Likert-type scale 
0 I do not have this symptom 
1 I have this symptom, it doesn’t bother me 
2 I have this symptom, it bothers me a little 
3 I have this symptom, it bothers me 









































































Questions 35-49 related to physical symptoms. Answers are represented in the next table and graph. 
 
Table 18. Answers to questions 35-49 
Questions/ Scores 0 1 2 3 4 
35: Difficulty falling or staying asleep 16 (57.1) 2 (7.1) 2 (7.1) 2 (7.1) 4 (14.3) 
36: Feeling dizzy or light-headed 18 (64.3) 3 (10.7) 3 (10.7) 0 (0) 4 (14.3) 
37: Fatigue or loss of energy 6 (21.4) 2 (7.1) 8 (28.6) 5 (17.9) 5 (17.9) 
38: Pain, numbness or tingling in the 
hands or feet 
17 (60.7) 4 (14.3) 3 (10.7) 0 (0) 4 (14.3) 
39: Nausea or vomiting 16 (57.1) 0 (0) 4 (14.3) 3 (10.7) 4 (14.3) 
40: Diarrhoea 26 (92.9) 0 (0) 0 (0) 0 (0) 2 (7.1) 
41: Loss of appetite 18 (64.3) 2 (7.1) 4 (14.3) 1 (3.6) 3 (10.7) 
42: Shortness of breath 13 (46.4) 0 (0) 5 (17.9) 3 (10.7) 7 (25.0) 
43: Coughing up blood 28 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
44: Skin problems, such as rash, dryness 
or itching 
12 (42.9) 5 (17.9) 4 (14.3) 3 (10.7) 4 (14.3) 
45: Ringing in ears or loss of hearing 12 (42.9) 5 (17.9) 3 (10.7) 3 (10.7) 2 (7.1) 
46: Joint pains 10 (35.7) 3 (10.7) 3 (10.7) 3 (10.7) 9 (32.1) 
47: Ongoing pain at injection sites 26 (92.9) 0 (0) 0 (0) 0 (0) 2 (7.1) 
48: Confusion or trouble remembering 11 (39.3) 8 (28.6) 4 (14.3) 2 (7.1) 3 (10.7) 
49: Tremors, shaking or fits 23 (82.1) 1 (3.6) 2 (7.1) 0 (0) 2 (7.1) 
 
Questions 50-60 concerned psycho-social issues and are depicted in the table and graph below: 
 
Table 19. Answers to questions 50-60 
Question 0 1 2 3 4 
50: Feeling sad, down or depressed 11 (39.3) 4 (14.3) 4 (14.3) 4 (14.3) 5 (17.9) 
51: Feeling suicidal 26 (92.9) 0 (0) 1 (3.6) 0 (0) 1 (3.6) 
52: Feeling hopeless 16 (57.1) 1 (3.6) 2 (7.1) 4 (14.3) 5 (17.9) 
53: Feeling anxious or scared 18 (64.3) 0 (0) 3 (10.7) 2 (7.1) 5 (17.9) 
54: Having remorse or regret 13 (46.4) 3 (10.7) 5 (17.9) 2 (7.1) 5 (17.9) 
55: Feeling like you’re not coping 17 (60.7) 2 (7.1) 5 (17.9) 1 (3.6) 3 (10.7) 
56: Feeling stigmatised by family, 
relationships are limited 
21(75) 2 (7.1) 0 (0) 0 (0) 5 (17.9) 
57: Feeling stigmatised by community 
or discriminated against 
24 (85.7) 0 (0) 0 (0) 1(3.6) 2 (7.1) 
58: Feeling stigmatised by health care 
professionals, abandoned 
23 (82.1) 2 (7.1) 0 (0) 3 (10.7) 0 (0) 
59: Feeling isolated and lonely 16 (57.1) 1 (3.6) 2 (7.1) 2 (7.1) 6 (21.4) 
60: Worried about finances/ money 4 (14.3) 2 (7.1) 1 (3.6) 2 (7.1) 19 (67.9) 
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Figure 17. Prevalence and burden of physical symptoms  
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The next contingency table compared “depression” with several variables: 
 
Table 20. Contingency table comparing “depression” with “difficulty taking tablets”, “financial worry”, “suicidal 
ideation” and “hopelessness”. 
 


















14 (50.0) 3 (10.7) 14 (50) 3 (10.7) 2 (7.1) 15 (53.6) 11 (39.3) 6 (21.4) 
Depressed-N  
N (%) 
4 (14.3) 7 (25.0) 10 (35.7) 1 (3.6) 0 11 (39.3) 1 (3.6) 10 (35.7) 
Spearman’s Rank Correlation: Depression (x) vs difficulty taking tablets (y) (using online calculator 
found at Social Science Statistics website(97))  
The value of R is 0.33776 and the two-tailed value of P is 0.07877. By normal standards, the association 
between the two variables would not be considered statistically significant. 
Spearman’s Rank Correlation: Depression (x) vs hopelessness (y) (using online calculator found at 
Social Science Statistics website(97))  
The value of R is 0.64595 and the two-tailed value of p is 0.0002. By normal standards, the association 
between the two variables would be considered statistically significant. 
Spearman’s Rank Correlation: Depression (x) vs financial worries (y) (using online calculator found at 
Social Science Statistics website(97))  
The value of R is 0.28301 and the two-tailed value of p is 0.14448. By normal standards, the association 
between the two variables would not be considered statistically significant. 
 
Each respondents’ total symptom burden score was plotted. The average number of symptoms was 
10.25. In the Figure below, red data points mark those respondents who were referred urgently. 






















Number of Palliative care positive scores
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Cronbach’s Alpha analysis was performed on questions pertaining to psychosocial concerns to determine 
the consistency of patients’ answers and their insight into the questions. An alpha value above 0.7 was 
considered consistent. (98)   
 
                          Table 21. Cronbach’s alpha analysis 
Items Cronbach Alpha 
All items 0.8474 
Question 50 (Depression) excluded 0.7879 
Question 60 (Financial worries) excluded 0.8791 
Question 55 (Coping) excluded 0.8209 
Question 52 (Hopelessness) excluded 0.7965 
Question 53 (Anxiety) excluded 0.8293 
Question 59 (Feeling isolated and lonely) excluded 0.8049 
 
Therefore, the respondents had answered the questions consistently and reliably. Furthermore, Multiple 
Logistic Regression analysis was carried out to determine how quality of life, functional status and 
symptom burden (measurement variables, x1, x2 and x3 respectively) affected Palliative Care Referral 
(binomial, independent variable, y:“0” no referral, “1” referral. 14 cases had y=0; 14 cases had y=1) -
using online calculator found at www.statpages.info/logistic.html 
 
Table 22. Univariable analysis vs multivariable analysis 
 Univariable analysis         Multivariable analysis with FS Multivariable analysis with FS (0/1) 
Var Co-eff P OR 95% 
CI 
Co-eff P OR 95% 
CI 
Co-eff P OR 95% 
CI 
x1   0.1583 0.0287 1.1715 1.0166-
1.3500 
0.0724 0.4549 1.0751 0.8892-
1.2999 
0.0756 0.4289 1.0786 0.8943-
1.3009 
x2 (a) 0.5637 0.1815 1.7571 0.7687-
4.0166 
0.1516 0.7879 1.1637 0.3857-
3.5111 
    
x2 (b) 0.7732 0.5485        2.1667 0.1734 
27.075 
    0.3221 0.8312 1.3800 0.0714-
26.687 
x3  0.1365 0.0042        1.1463 1.0440-    
1.2585 
0.1254 0.0112 1.1336 1.0289-
1.2490 
0.1270 0.0101 1.1354 1.0306-
1.2508 
[Var= variable; Co-eff= co-efficient; p= p-value; OR= Odds ration; 95% CI= 95% confidence interval; FS=functional 
status]; x 2 (a)= functional status as scored on ECOG score; x 2 (b)= functional status as binary score :“0” is ECOG 
scores 0,1,2 and “1” is ECOG scores 3,4,5. 
 
The use of the binary score of ECOG did not make a difference. Symptom burden scores showed a 




4.8   Qualitative analysis of data retrieved from open questions 
Question 61. Please tell me more about what troubles you the most? 
Question 62. What else do I need to know about you to be able to provide good care? 
 
The themes that emerged were: 
(1) Financial concerns 
(2) Concerns for Physical safety 
(3) Dysfunctional social relationships 
(4) Impact of DR-TB infection and treatment 
(5) Concerns about HIV co-infection 
(6) Patients’ sense of loss of autonomy and self-worth 
(7) Inadequate Therapeutic relationship 
 
Theme (1) Financial concerns: 
Several of the communities that were visited were impoverished and lacked decent infrastructure, 
amenities and accommodation. Many participants lived in unsafe locations and were concerned about the 
inadequacy of their housing. Households were often overcrowded. Participants had limited choice in 
where or with whom they lived due to their financial insecurity. Several patients were unable to access 
disability grants because of lapsed applications, missing Identity documents and asylum seeker status. 
The worry about the lack of money predominated: it caused stress and guilt due to the participant’s 
inability to care and provide for their family (in terms of shelter, food, schooling and clothing) and thus 
fulfil parental responsibilities. Limited finances made transportation to clinics or visiting children 
difficult or impossible. Financial concerns worsened physical and psychological symptoms and strained 
relationships. Pre-existing financial constraints were exacerbated by the participant being unwell and 
incapacitated.  
▪ “Ek moet die waarheid praat – dis die geld” (I must be truthful – it’s the money) – participant 
“AD”  
▪  “I’ve got nothing at home” – participant “L” 
▪ “Ek kan nie uitkom nie” (I can’t make ends meet)- participant “O” 
 
Theme (2) Concerns for Physical safety: 
Physical safety (personal, family, business and belongings) was a real concern for a number of 
participants. Their safety had been threatened by gangsterism, living in unsavoury neighbourhoods and 
opportunistic sexual exploitation. The safety of participants’ family members was a concern when 
admission to BCH was considered.  
▪ “dinge wat ek sien nie reg vir my kind of my nie” (The things that I see [that are going on around 
us] are not right [beneficial] for my child or me)- participant “Y” 
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Theme (3) Dysfunctional social relationships: 
Several respondents had dysfunctional relationships that distracted from efforts to regain health and 
resulted in isolation. Some relationships were economically, physically and emotionally abusive. A few 
participants had been separated from their children by social circumstances –such as the recent fire in 
Imizama Yethu, social welfare child protection, gangsterism and their children’s drug usage - and longed 
for contact.  
▪ “my familie– hulle verstoot – maak probleme vir my” (my family, they reject me and make 
problems for me)- participant “Y” 
▪ “[I]can’t even take my children to school”- participant “L” 
▪ “Ek kry nie die liefde” (I don’t get love) – participant “O” 
 
Theme (4) Impact of DR-TB infection and treatment:  
▪ Participants described poorly controlled physical symptoms  
“to suffer like this, it’s better for me to go [die]”- participant “R” 
▪ The prescribed treatment, with the accompanying pill burden and side-effect manifestations 
affected patients 
“its scary actually” – participant “N” 
 
Theme (5) Concerns about HIV co-infection: 
For a number of HIV-positive patients, having HIV was worse than having DR-TB in that the stigma of 
HIV concerned them more than having DR-TB, and DR-TB was perceived as trivial compared to the 
fatality and incurability of HIV. 
▪ “As jy HIV is, is jy vrot” (If you have HIV – then you’re [considered] rotten) – participant “O” 
▪ “Die een maak jou gesond, die ander een maak jou dood” (This [DR-TB] you’ll get better from, 
this [HIV] will kill you”) – participant “O” 
▪ Participant “O” requested a cure for HIV to be found. 
 
Theme (6) Patients’ sense of loss of autonomy and self-worth: 
Patients struggled with feeling out of control and unable to make their own decisions. 
▪ Incapacitating physical symptoms led to a loss of independence.  
“[Die] pille maak my dronk – dan kan ek niks doen vir die dag nie” (The pills make me feel 
drunk- then I can’t do anything during the day)-participant “X” 
 “My life is not going to be the same again”-participant “R” 
▪ Patients felt uncertainty for the future: they worried about being admitted to BCH, about future 
treatment opportunities and about not being cured. 
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“[there’s] lots of promises for treatment, but nothing happens”- participant “G” 
 
Some participants expressed a sense of worthlessness 
▪ “niks werd vir niemand nie” ([“I’m] not worth anything for anybody”)- participant “O” 
▪ “somtyds voel ek so vuil” (“sometimes I feel so dirty”) – participant “P” 
 
Theme (7) Inadequate Therapeutic relationship: 
Participants desired a more therapeutic relationship with their HCP: to be treated with respect and have 
their complaints addressed. 
▪  “om die moiete werd te voel” (To feel like I matter)- participant “E” 
▪ “it is true – I’m not lying – they assume that I don’t want to take my medication; but I have 
complained about the same problem for 6 months – and still don’t feel better”- participant “R” 
▪  “[I] can’t swallow the tablets without eating – and [I’m] not eating at the moment” – participant 
“L” 
 
4.9   Qualitative analysis summary of all the narrative data  
All the narrative data from the patients’ interviews as well as questions 61 and 62 were analysed 
collectively and arranged into two themes or responses to patients’ vulnerability. Vulnerability had led to 
the development of either despair or resilience. The theme relating to despair looked at the personal 
context and widened to include the family, community and the current health care system context. The 
theme relating to resilience showed attitudinal shifts and adjustments that stemmed from good 
therapeutic relationships and inner resolve. 
 
Table 23. Emerging Themes from Qualitative analysis 
 VULNERABILITY leading to: 
(a) Despair (b) Resilience 
In personal context Lack of autonomy 
Lack of dignity 
Spiritual pain 
Adaptive medication-taking techniques 
Inner strength and purpose 
In community context Concern regarding Physical safety 
Lack of empathy/ stigma 
 
In family context Weight of responsibilities 
Lack of empathy/ stigma 
 
Within Health care system Lack of palliative care approach by HCP 
Negative connotations towards BCH 




Theme (a) Vulnerability/ Despair: 
(1) In personal context 
Participants despaired about their personal circumstances where there were unfulfilled wishes, poor 
self-determination, poor support and loss of selfhood. 
Lack of autonomy: 
▪  “I wish for money – to have a life I can afford. If I want to do something to be able to do it” –      
         participant “I” 
▪ “without income I am lost” – participant “L” 
▪ “I’m a prisoner in my own body” – participant “Z” 
▪ Participant “F” wanted to be able to get his salvage treatment regimen from his clinic and not be 
forced to be admitted to BCH. 
 
Lack of dignity: 
▪ “I have to beg my neighbour for food for myself and my daughter” – participant “U” 
▪ “Am I disgusting?”- participant “N” 
▪ “If I die, don’t tell anyone, just call my @£$%^&* children” –participant “O” recounting 
what her sister said before dying from MDR-TB 
 
Spiritual pain: 
The following comments suggested spiritual suffering: 
▪  “I cry every day” – participant “L” 
▪ “I will never have peace” – participant “U” 
▪ “I’m a prisoner in my own body” – participant “Z” 
 
and descriptions of having lost identity, purpose and meaning:  
▪ “Ek voel klaar – ek is niks werd vir niemand nie” (I feel empty – I’m not worth anything to 
anybody) – participant “O” 
▪  “Nothing comes right, nothing comes my way” – participant “L”. 
▪ “I don’t know where I stand” – participant “G” 
  
Some respondents expressed their religious struggles in the context of being unwell:  
▪ “TB kom van die Here af”(TB comes from God)- participant “Q” 




Others asked rhetorically: 
▪ “Why am I still taking the tablets if I’m going to vomit?” – participant “Z”  
▪ “There’s always the worry- is it your time?” – participant “AA” 
▪ “When is this TB going to be finished?” – participant “AE” 
 
The persistence of some symptoms possibly indicated a spiritual component – Participant “R” had 
experienced the same symptom for 6 months. 
 
(2) In community context: 
      Within participants’ communities they felt isolated by fear or stigma. 
  Concern regarding Physical safety: 
▪ Participant “L” claimed to be watched by her son’s rival gang members. 
▪ Attendance at the clinic was obstructed by gang rivalry and danger. 
▪ “The ‘Americans’ [gang name] are here at the clinic – hulle kyk skeef aan my” (The 
Americans watch me suspiciously at the clinic) –participant “Y” 
 
Lack of empathy by community members/stigmatisation: 
▪ “[my] friends have run away” –participant “S”  
▪ Whilst participant “H” was in BCH, her son had been bullied and teased with taunts of his 
mother going to die.  
▪ Participant “S” was deliberately turned away from the community hall when seeking refuge 
from a fire in her township. 
 
(3) In family context: 
Participants also felt despair and loneliness within their family unit. 
Weight of responsibilities: 
▪ “I must be alive for my children and grandchildren” –participant “J” 
▪ “I’m letting my children down, I can give [bread] today, but not tomorrow”– participant 
“L” 
 
Lack of empathy/ stigmatization: 
▪ “nie een van hulle het ‘n phone call gemaak om te sien hoe dit gaan” (“not one family 
member had bothered to make a phone call to see how I was doing.”)- participant “X” 
▪ “You’re already dead!” – participant “U”’s boyfriend of her 
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(4) Within the health care system: 
Participants’ disappointment extended to the current health care system – occasionally with 
justification. 
▪ “find a tablet that will work for me” – participant “G” 
 
Lack of palliative care approach by HCP: 
A holistic approach to the DR-TB patient was not always portrayed. 
▪ “these tablets are making me sick” – participant “M” 
▪ “to suffer like this, it’s better for me to go [die]”- participant “R” 
▪ “who is going to look after my children [if admitted to BCH]?” – participant “U” 
 
Lack of dignity: 
Several patients felt angry and hurt by attitudes and behaviours within the health care system that 
belittled them. 
▪ “They treat you like you’re a germ” – participant “N” 
▪ “Don’t show people my tablets!” – participant “T” 
 
Negative connotations towards Brooklyn Chest Hospital 
BCH was not perceived or experienced in a positive light by those anticipating admission or those 
previously admitted. 
▪ “The yellow one[tablet] – the Brooklyn one – is hard to swallow – it tastes worse and 
worse.” – participant “S” 
▪ “[you] give us spaghetti bolognaise – we don’t eat that”- participant “F” regarding 
culturally inappropriate meals at BCH 
▪ “Daar gat ek dood gaan – dis beter as ek aangaan by die huis” (I’ll die there – it’s better if 
I continue [treatment] at home) – participant “AF” 
 
Theme (b) Vulnerability leading to Patients’ resilience: 
Some patients had adapted to their diagnosis and circumstances in a positive way showing resolve, 
motivation and purpose. This was seen in the value placed on tablet adherence, recovery and their 
therapeutic relationship within the health care system.  
 
(1) Adaptive medication-taking techniques 
Several participants described an acceptance and understanding of the treatment regimen and 
described novel ways of taking all their required medication. 
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▪ “ek vat die kleinjies eerste – dan wag – die capsules – hulle is die moeilikste” (I take the small 
ones first then wait – the capsules are the most difficult)- participant “P” 
▪ “I drink it like smarties*” – participant “I” 
▪ “I trust the clinic” – participant “S” 
 
 (2) Inner strength and purpose:  
Despite their circumstances, several patients expressed acceptance of their predicament and had 
found existential meaning, rising above their suffering and challenges. 
▪ “I’m never going to give up” – participant “I” 
▪ “It is here, I must face it”- participant “F” 
▪  “I’m not the only one with the disease” – participant “J” 
 
(2) Therapeutic relationships: 
Some clinic staff were commended for their care. 
▪ “Ek geniet dit eintlik om kliniek toe te kom.” (I enjoy coming to the clinic actually) – 
participant “W” 
▪ “The TB sisters have treated me with dignity – my own people don’t treat me like this” – 
participant “Y” 
 
Referrals to HCPs at local clinic for further management: 
Referred: n (%) Yes: 14 (50%) No: 14 (50%) 
There were several issues per referral that needed addressing. 

































































5.1   Introduction 
This study’s aim was to determine the palliative care needs of DR-TB patients. The objectives were: to 
assess quality of life and symptom burden; and to assess for a link between these variables to palliative 
care need. The researcher demonstrated that the higher the symptom burden, the lower the quality of life 
and the lower the functional status, the greater the need for providing palliative care services in the 
southern sub-district of Cape Town. 
 
The communities in this geographical area of Cape Town were multi-cultural, multi-lingual and differed 
in socio-economic status. Chapter 2 considered the difficulties of assessing palliative care needs of DR-
TB patients in a culturally sensitive, demographically representative manner - when no tool existed for 
this purpose. Chapters 2 and 3 mentioned the research that was undertaken to tailor the questionnaire 
used in this study. 
 
A discussion follows on the quantitative and qualitative findings of the research questionnaire. 
 
5.2   Demographic details 
De Vallière and Barker’s study(68) considered which pulmonary TB patients were at risk of dying using 
a modified ECOG score - and showed that the age category 35-49 years was independently associated 
with a higher mortality (reasons for this were not given in the paper). In the current study, fifty percent of 
patients fell into this age category. Figure 9 showed that almost two-thirds of the urgent referrals were 
from this 35-49 year age group and that all those having a palliative care score of >15 were in this age 
group. Their median ECOG, APCA-POS and symptom burden scores were compared with those 
participants’ whose ages were younger or older than 35-49 years - but was not found to be statistically 
significant. This study’s sample size was not large enough to establish a clear relationship between this 
age group and high palliative care need. 
  
Female participants scored higher in their symptom burden scores, however this was not deemed 
statistically significant. The median APCA-POS scores for males and females were equal. Chang et al’s 
systematic review (that referenced Banerji et al(99) and Hongthiamthong et al(100)) showed that somatic 
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symptoms of TB were more common in men and middle-aged individuals (63) – however that finding 
was not collaborated in this current study. 
 
All but one participant was South African and this patient was a Burundian refugee. A “refugee” has a 
high risk of requiring palliative care support to cope with an infection such as DR-TB. (101)  This 
participant had the highest combined stigmatisation total: stigmatised by family or friends, by the 
community and by health care professionals. His pre-existing language barriers and ex-prisoner status 
contributed to the stigmatisation he experienced.  
 
In this study, none of the respondents had received a tertiary education. More than half of the 
respondents had left school before reaching Grade 7. Poor literacy had been shown to limit health literacy 
- exacerbating patient vulnerability, impacting health-seeking behaviour, impairing understanding of 
disease management, compliance and decreasing employability. (102)  It therefore impacted on the 
person’s physical, emotional, psychological and social wellbeing. The literacy of this study’s cohort 
compared to the literacy average of the City of Cape Town was more than seven times worse(103) – 
which contextualised the challenges faced in preventing and managing TB in these vulnerable 
communities. 
 
The questions relating to the number of windows in the patient’s dwelling, number of people in the 
household and other people at home with TB helped gauge the living conditions of the participants and 
the infection risk within their households. This information contextualised the research findings. Of 
concern was the participant who lived with nine others (including children) in small quarters with only 
one window. Another participant’s answers led the researcher to identify a child (younger than 5 years) 
not on prophylactic TB medication. The researcher was ethically obligated to refer this child to the local 
health authorities, which was done with the consent of the adult participant. 
 
Almost two-thirds of this study’s participants had had TB before – reflecting the burden of TB on 
individuals and their families. One participant (“AF”) volunteered that he had been treated for TB six 
times previously and another participant (“AE”) had had TB three times – including MDR-TB. The 
length of time between their previous episodes and current DR-TB infection was not elucidated, but re-
treatment TB patients have been recognised as being at high risk of developing DR-TB. (8)  There was 




The trial participants were at different stages of their treatment journey - which reflected the cross-
sectional nature of the study and gave an indication of whether the participants were receiving injectable 
treatment in the initial phase. The length of time since diagnosis provided a reference point within the 
proposed disease trajectory (see discussion later).  
 
The question regarding current usage of TB drugs stirred up strong emotions for three participants not 
currently taking medication. It highlighted the ethical complexities and challenges of DR-TB 
management: two patients had failed treatment and TB medication had been suspended or withdrawn. 
See Appendix 21 for the indications of DR-TB medication withdrawal. Both of these participants 
continued to live in the community.  
 
One patient had refused admission to BCH for participation in a trial because: (a) BCH was too far away 
from his community and family; (b) he was concerned for his family’s safety in his absence; (c) and he 
complained about the culturally inappropriate food at BCH “[you] give us spaghetti bolognaise – we 
don’t eat that!” This patient’s powerlessness and loss of autonomy in negotiating his future management 
caused mistrust in the therapeutic relationship and blame on HCPs. Senthilingam’s findings in 
community-based uncured XDR-TB patients also reported mistrust of HCPs, unmet needs and the 
preference to receive care and treatment in the community. (35)  Upshur et al described an individual 
having the potential to be both a victim and vector of disease (104) – and in this participant’s instance, 
the ethical dilemma of justifiable forced admission was raised.  
 
The other respondent was waiting on a salvage regimen application, having had treatment withdrawn six 
months prior due to treatment futility. He described a sense of abandonment and hopelessness that 
highlighted the disproportionate power differential between a treatment failure patient and the treating 
authorities. 
 
The third patient had missed his medication for one week after a quarrel with the TB sister - who had 
allegedly withheld his “pap”(porridge) supplement. According to clinic staff, patients qualify for a 
porridge supplement according to their Body Mass Index and as prescribed by a dietician.  
 
In this research study, approximately half of the trial participants were co-infected with HIV and all but 
one were taking ARVs currently. This respondent claimed that the clinic doctor had withdrawn her 
ARVs temporarily. All respondents had been tested for HIV – conforming to the South African National 
TB Guidelines’ stipulation that all confirmed TB patients be offered HIV counselling and testing. (8)  
Furthermore, the guidelines stated that co-infected TB patients, irrespective of CD4 count, required 
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ARVs. Ideally, HIV and TB services should be integrated. 
 
In Osman and colleagues’ Cape Town study, HIV co-infected DS-TB patients were more than twice as 
likely to die as compared to HIV-negative patients. (81)  They also found that HIV-positive women (with 
DS-TB) had a higher risk of death than their male counterparts. (81)  Thus, the possibility of HIV-
positive patients experiencing worse quality of life or worse DR-TB symptoms than HIV-negative 
patients was explored. Lowther et al had found that HIV-positive people reported experiencing lower 
quality of life compared to HIV negative people (notwithstanding DR-TB)-attributing this to their 
physical and psychological symptoms. (105)  A number of studies reported that co-infection with HIV 
substantially increased the mortality rate of patients with MDR-TB or XDR-TB(13,15) – with HIV 
infection being the strongest predictor of death among MDR-TB patients.(67) 
 
In Avong’s Nigerian study of patients on MDR-TB treatment, no differences were observed in the risk of 
adverse events between HIV infected and uninfected patients. (106)  On the contrary, Sagwa’s Namibian 
study(107) looking at the adverse events reported by DR-TB patients on treatment, found that HIV-
positive DR-TB patients experienced more moderate-to-severe adverse events compared with their HIV-
negative counterparts. Sagwa recognised that HIV exacerbated the already severe psychosocial burden 
faced by DR-TB patients (46,76) and was an additional stressor for participants.  
 
In this study, with a relatively small cohort of patients, HIV co-infected DR-TB patients scored slightly 
worse (higher) on the APCA-POS score compared to HIV-negative patients (see Table 9). Furthermore, 
HIV co-infected patients had similar scores for ECOG median scores compared to HIV-negative patients 
and scored lower in median symptom burden scores. Thus HIV co-infection did not make a significant 
difference to the quality of life or symptom burden of this cohort of patients.  
 
The pill burden and the accompanying side effects were mentioned repeatedly when patients were asked 
what bothered them the most and were a significant finding in the thematic analysis. Pill burden is 
associated with poor drug regimen adherence - and both pill burden and side effects pose challenges 
when TB and HIV are treated concomitantly. (108)  Almost two-thirds of patients were required to take 
more than 20 tablets each day and the same percentage found taking their tablets difficult. Some of those 
taking less than 20 tablets also found taking their tablets a problem.  
 
The questionnaire in this research study did not ask specifically about adherence. Daftary and colleagues, 
in their study of ARV adherence of DR-TB/HIV co-infected patients in South Africa, reported that 
patients expressed a preference for ARVs over DR-TB treatment because of better tolerability, fewer 
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pills and a commitment to ART. (109)  The researcher also found that some patients feared the stigma 
and incurability of HIV more than DR-TB (Participant “O”:“TB is nie groot nie” (TB is not [a] big 
[deal]”[compared to HIV]). Potentially, improper adherence to MDR or XDR-TB treatment could 
amplify TB drug resistance. (109)  Participant “H” had displayed all her tablets during the interview and 
exclaimed, “I can’t do it! I want to default!” Defaulting sentiments require urgent intervention and 
support.  
 
The results showed that there was no association between reports of depression and difficulty taking 
tablets – although DiMatteo found that depression was one of the strongest predictors of patient non-
adherence to medical management. (110)  
 
The cohort was divided equally between smokers and non-smokers. Active smoking is a known risk 
factor for death when having TB. (8)  No correlation with smoking and increased palliative care need 
was found. A number of patients described members of their family that were drug users and the 
detrimental drug culture in which they lived. The recreational drugs mentioned were dagga*, “tik” ^ and 
mandrax$.  
 
Participants mentioned that their inability to work had often been for extensive periods- during the six 
months whilst receiving injectables and up to 1 year following diagnosis. Two studies-Isaakidis et al and 
Morris et al respectively  (46,111)  - reported that DR-TB resulted in an inability to work because of drug 
side effects and incapacitating depression at the time of diagnosis, resulting in loss of income and 
diminishing responsibilities. Therefore, poorly managed symptoms and poor functional status 
perseverated the cycle of vulnerability and suffering. 
 
5.3   ECOG score – an assessment of functional status 
The researcher had defined “palliative care need” as a score of greater than or equal to “3” on the ECOG 
score. Only three respondents described themselves in that way and required referral for urgent 
intervention. Recall de Vallière and Barker’s study which showed that patients with a performance status 
of “3” or “4” (at time of diagnosis and initiation of TB-treatment) had a strong association with early 
death. (68)  However, the study’s recruitment strategy and safety precautions precluded home visitations 
and thus introduced unavoidable sample bias. 
__________________________________________________________________________ 
^ 
“Tik” is the South African street name for crystal methamphetamine*;  
“Dagga” is a South African stree tname for the drug marijuana;  
$ 
“Mandrax” is the sedative-hypnotic drug methaqualone 
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None of the respondents reported being completely disabled and unable to carry out self-care (score “4”). 
Within this cohort of patients, the ECOG score might have been inflated despite symptom burden, 
considering the large burden of parental responsibility and financial strain highlighted in the qualitative 
data.  
 
In this research study, the ECOG score could not be linked meaningfully to the median APCA-POS or 
median symptom burden scores, due to the small sample size (n=28). 
 
5.3.1   The Proposed DR-TB Disease trajectory 
Plotted disease trajectories depict the impact of the disease on the individuals’ functional status (such as 
the ECOG score). The researcher, after supervisory input, discussion with experienced DR-TB 
colleagues and from information gathered from the Literature Review, proposed a disease trajectory for 
DR-TB infection.  
 
Figure 21. Proposed DR-TB trajectory over time 
 
               
 
The “pre-TB baseline” functioning, as depicted in the graph, would be determined by the individual’s 
age or co-morbidities. After DR-TB diagnosis, functional status might be impacted by the patient’s 
symptom burden (112)  or improve having started DR-TB specific treatment.  
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Further positive and negative fluctuations along the trajectory might be due to DR-TB complications 
(such as pleural effusion, TB dissemination, development of XDR-TB), medication side effects, co-
morbidities or changes in psycho-socio-economic circumstances. Deterioration in health and functional 
status might result in constructive health-seeking behaviour or alternatively poor compliance, defaulting, 
loss to follow-up and further deterioration. The plummet in functional status indicated high risk of 
mortality and would correspond to an ECOG score of 3 or 4.(68,86) 
 
The proposed DR-TB disease trajectory anticipated patients’ potential needs and outcomes (113)  and 
allows preparation for the care required. It highlighted the relevance of applying a palliative care 
approach alongside curative treatment from the time of diagnosis and reinforced the need for continuity 
of care. DR-TB patients might die at any point along the trajectory – death may be sudden and 
unforeseen (as the researcher realised with the unexpected deaths of two participants in the pilot study). 
As an educational tool, such a DR-TB trajectory would also help patients to cope with the illness by 
improving awareness and empowerment. 
 
Functional status was shown in the literature to link QoL and symptom burden. 
 
5.4   Quality of life evaluation 
The literature indicated that TB affected quality of life both directly and indirectly. (63)  The DR-TB 
patient’s perception of QoL was a reflection of a “complex construct of influences” (55)  - the DR-TB 
infection, anti-TB medication, “socioeconomic background and cultural context”, (114)  immigrant 
status, other co-morbid conditions, (75)  financial concerns, symptom burden and spiritual issues. The 
once-off use of the APCA African POS score in this study gave an indication of the trial participants’ 
quality of life. 
 
All but three patients denied experiencing pain; but a number described experiencing overwhelming and 
moderate pain. The type of pain described was mostly physical but occasionally emotional. 
 
The WHO Global Atlas of Palliative Care(45) estimated palliative care needs according to pain 
prevalence. In their analysis, DR-TB ranked second in overall pain prevalence (90%) after cancer (35-
96%), and above HIV/AIDS (63-80%). (45) In this research study, just more than half of the participants 
reported experiencing pain, and therefore by the Global Atlas estimation, would imply the same 
percentage having palliative care needs. However, as Figure 9 indicated, the prevalence of palliative care 
need was far greater –each participant was determined to have a “palliative care need” in this study.  
 
 75 
Those patients who answered “no pain/ 0” in the APCA-POS were compared with those who described 
having pain. Patients who had experienced a degree of pain, scored higher on their median APCA-POS, 
ECOG and symptom burden scores. The differing ECOG and symptom burden scores (no pain vs pain) 
were statistically significant. Despite a patient not reporting pain, they still had significant palliative care 
needs that warranted referral and escalation of care.  
 
Recall the WHO definition of palliative care: “Palliative care is an approach that improves the quality of 
life of patients and their families facing the problems associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychological and spiritual”. (49) 
 
The researcher found that more than two-thirds of those with pain were referred urgently as well as a 
quarter of those reporting “no Pain/0”. Thus the absence of pain did not dismiss the need for palliative 
care. Therefore, the researcher believes that in the context of DR-TB, the prevalence of “palliative care 
need” should not be estimated solely on one variable – pain prevalence. Paradoxically, however, 
“palliative care need” existed in the presence of only one significant variable or uncontrolled symptom. 
 
The next question in the study indicated that respondents were bothered mostly by respiratory (shortness 
of breath, coughing, tight chest) and gastro-intestinal symptoms (nausea, vomiting, epigastric pain, 
heartburn). There was significant prevalence of these physical symptoms. The top five “other” symptoms 
that bothered patients in question 29 were: coughing (21.4%), nausea (21.4%), vomiting (7.1%), 
problems with eyes (7.1%) and stress (7.1%). Summarised, these five symptoms were due either to the 
tuberculosis infection, DR-TB drug side effects or socio-economic concerns. 
 
The researcher sensed that some respondents were unable to distinguish their worry related to DR-TB 
from other worries, such as concomitant medical problems (such as Diabetes or HIV) or social 
circumstances. The “degree” of worry was moderated by confidence in the anti-tuberculosis medication- 
one lady denied being too worried because “jy kry pille”(you get pills) participant “P” – as well as by 
the resources available to them –“I looked it up on my phone [internet]” (participant “N”) and “other 
people’s prayers helped”(participant “N”). 
 
The question regarding the ability to share feelings with others hinted at their disclosing of their 
diagnosis and provoked strong emotions in some participants, highlighting abusive, broken or strained 
family relationships, limited support and social isolation. One out of the nine participants who had 
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difficulty sharing their feelings, reported feeling stigmatised by her family due to DR-TB. Several 
participants had chosen not to burden their families by withholding their diagnosis.  
 
5.5   Assessment of patient’s Symptom burden 
Brown et al commented that, “illness … cannot be understood independently of the societies in which 
people live”. (55)  In this study, many patients were burdened by their inherent societal context, added to 
which were the symptoms due to DR-TB.  
 
The dominant symptom was anxiety related to financial worry (see Figure 17). In the analysis of the 
qualitative data, the worsening of pre-existing social issues overshadowed the DR-TB infection per se. 
This is in keeping with Chang et al’s comment that “the social and emotional burden of disease can equal 
and even exceed the physical impact of illness”. (63)  The other symptoms that had high percentages - 
scoring “4” on the Likert scale- were joint pain (32.1%), shortness of breath (25%) and feeling isolated 
and lonely (21.4%).  
 
Further discussion of each symptom category follows: 
 
5.5.1   Physical symptoms 
Chapter 2 discussed how physical symptoms were attributed to the mycobacterial infective process, 
concomitant illnesses or anti-tuberculosis drug side effects (see Appendix 21 for anti-tuberculosis drug 
abbreviations). The results showed that respondents were hampered by shortness of breath (51%, with 
25% scoring “4”), but fatigue was the most frequent (79%) and severe symptom reported by trial 
participants. Complaints of joint pains (64%) (Z,FQs) (19)  were also frequent and debilitating (32.1% 
scoring “4”). Symptoms such as paraesthesia (Cs,Trd,S,Km,Am,Cm,Eto/Pto,FQs), nausea and vomiting 
(Eto/Pro,PAS,Cm,E,Z) and visual impairment (E) could be attributed to anti-TB drug side effects 
(responsible agents in brackets).(18) 
 
5.5.2    Psychological symptoms: 
Seventeen of the respondents described feeling some degree of depression, with five describing it as very 
worrisome. Atif’s study showed that MDR-TB patients on treatment were at high risk of depression at 
the start of treatment and even on completion of treatment. (115)  Thus, even though eleven respondents 




The association between “Depression” and “Hopelessness” was statistically significant. Two patients had 
considered suicide and were referred urgently to the local clinic doctor.  
 
Thomas et al’s systematic review of issues challenging DR-TB patients listed prevalent psychological 
issues as being: “hopelessness, fear, perceived loss of self-identity, low self-esteem, feeling of guilt, 
isolation and depression”.  (22)  In this research study, “hopelessness” and “isolation” have been 
described rather as spiritual issues. 
 
5.5.3   Spiritual concerns: 
Spiritual wellbeing is a vital component of the impeccable assessment in integrating the palliative care 
approach. Chang’s review of TB literature did not find any studies that examined the impact of TB on 
spiritual wellbeing. (63)  Post and colleagues reported that neglecting spiritual needs might drive patients 
away from effective medical treatment  (116)  – with obvious detrimental consequences to the DR-TB 
patient and community. 
 
In this study, participants were asked directly about spiritual issues. Two themes emerged: those 
experiencing existential pain and suffering, and those able to find meaning and purpose in the midst of 
their current predicament. The ability of this cohort of DR-TB patients to adapt, develop better coping 
mechanisms and be resilient was observed by their accessing their faith, inner strength, family and 
community support or therapeutic relationships.  
 
5.5.4   Social symptoms: 
Vega et al. (117)  described a number of psychosocial concerns of DR-TB patients. They mentioned that 
DR-TB patients on treatment experienced fear and guilt associated with infectious risk. Likewise, several 
respondents in this trial expressed concern for their children’s risk of infection and had them tested for 
TB regularly at the clinic. An exception was participant (“F”), who had failed treatment, and was thus 
still contagious, who flagrantly did not observe infection precautions in his home and business. 
 
Vega et al (117)  also raised the issue of respondents having lost family members to DR-TB, which was 
raised by a number of patients in this study – some grieving the loss of two close family members. 
 
Patients’ anxiety was ameliorated by their confidence in the TB tablets or their management team. Those 
who were feeling anxious expressed fear of the possibility of not getting better, future treatment options 
and the threat to physical safety for themselves and their family. At the other extreme, Participant “U”’s 
denial of anxiety was due to her sense of hopelessness and fatalism. 
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“Stigma” was addressed in the questionnaire by asking the respondents three questions relating to family 
relationships, community situations and HCP interactions, but did not differentiate the basis for stigma – 
be it due to HIV, DR-TB, prison history, refugee status or homelessness. The researcher had anticipated 
the number of respondents experiencing stigma to be greater - after Lopez et al’s observations that the 
diagnosis of TB was “often accompanied by stigma, marginalization and shame”. (47)  One participant 
(“Y”) had even given a motivational interview for a local popular magazine regarding his experiences 
with DR-TB.  
 
The researcher deliberated whether the respondents understood the abstract concept of “stigma” with the 
answers from the direct questions - while, the patients’ anecdotal narratives indicated stigma in other 
ways. Some patients feared stigma or perceived there to be stigma when there was none. In other cases, 
stigma was “enacted” resulting in discrimination, (118)  being the targets for gossip, public insults, 
marginalisation and public humiliation during conflict.  
 
The patient with XDR-TB, who was not on treatment (participant “G”), reported not experiencing any 
stigma in the three categories. This was possibly inconsistent with the fact that this patient had been 
barred from attending the clinic because of his infectious risk.  
  
The non-South African participant (“T”) felt too intimidated to report his visual disturbances to the clinic 
and felt he was treated differently when his medication was dispensed. Senthilingam et al’s study(35) in 
the Western Cape also reported discrimination and humiliation by nurses when patients collected their 
medication.  
 
Lastly, Vega et al also mentioned “concomitant poverty” (117)  as being a significant concern of DR-TB 
patients. This was confirmed in both the qualitative and quantitative data of this research and witnessed 
on the community streets around the clinic sites.  Financial insecurity influenced decision-making 
regarding treatment, with employment superseding DOTS attendance or BCH admission. Nonetheless, 
financial insecurity also affected non-DR-TB community members (would-be control subjects) with 
South Africa’s high level of unemployment (27.7% in 2017 (119) ). Existing financial vulnerabilities 
would be exacerbated by the diagnosis of DR-TB. DR-TB costs the individual and family(77) in terms of 
lost employment opportunities whilst unwell, attending the clinic for treatment or stigma by employers; 




5.6    Limitations of the study 
Time and resource constraints as well as safety concerns imposed limitations on the study in terms of 
sample size. The small sample size restricted the conduction of statistical analyses such as linear or 
logistic regression models. These models would have been useful to identify predictors of participants’ 
concerns. 
 
The study’s confines were recruitment and measurement bias. The questionnaire did not ask about other 
significant co-morbidities – such as diabetes, alcoholism or cancer and the symptom burden list might 
have missed other important symptoms. The length of the questionnaire might have resulted in under or 
over reporting of symptoms. 
 
Because financial and social burdens played a dominant role in the participants’ quality of life - this 
study lacked the inclusion of a suitable comparison group (non-TB infected/ affected) within the southern 
sub-district of Cape Town with similar demographic, ethnic, cultural and socio-economic backgrounds 
and challenges.  
 
All but three participants were recruited and interviewed at the clinic. This might have resulted in the 
exclusion of more severely ill patients who would have been unable to attend the clinic. However, due to 
safety concerns, clinic visits were considered more appropriate.  
 
5.7   Conclusion 
Participants in this research study demonstrated substantial palliative care needs regardless of where on 
the DR-TB trajectory they were placed. Higher symptom burden scores correlated with a greater need for 
palliative care referral. In the context of the southern sub-district of Cape Town, these patients also had 
significant pre-existing socio-economic hardships and day-to-day concerns that needed to be addressed in 
order for improvement in all aspects of quality of life.  
 
The next chapter discusses the contextual and realistic aspects of providing palliative care to DR-TB 













6.1   Introduction 
Drug-resistant TB is a life-threatening infection - with a significant mortality rate. It poses an increasing 
problem globally, nationally and locally – particularly in vulnerable communities disadvantaged by 
socio-economic injustices. Recognising this, the WHO identified DR-TB patients as requiring palliative 
care. (45)  This need for palliative care has also been re-iterated in the End-TB strategies(59), the South 
African National MDR-TB guidelines(19) and the Hospice Palliative Care Association (HPCA) of South 
Africa’s Guidelines for providing palliative care to patients with tuberculosis.(58) 
 
A “needs-based” model of palliative care, rather than a “prognosis-based” model is promoted by the 
WHO. (52)  However, the literature proved scanty regarding what those palliative care needs of DR-TB 
patients might be. What is more, the literature did not identify a reliable, validated means of assessing 
these palliative care needs – particularly in a low-to middle-income setting. 
 
Therefore, this study aimed to assess the palliative care needs of patients with DR-TB infection within 
the southern sub-district of Cape Town by means of a researcher-designed questionnaire. This cross-
sectional study included twenty-eight patients at different stages of their disease trajectory. Their needs 
were documented in Chapter 4 and discussed further in Chapter 5. 
 
6.2   The findings of this research study 
Each respondent proved to have been impacted by DR-TB – with all respondents displaying at least one 
palliative care need (see Figure 9). A score of greater or equal to 10 in the palliative care need index of 
the questionnaire correlated with the necessity for referral for further management. The absence of pain 
did not exclude a need for palliative care in these DR-TB patients. Notably, the majority of those 
requiring referral were HIV co-infected and/or in the 35-49 year age category. Individuals were affected 
physically, psychologically, emotionally, socially, economically and spiritually- oftentimes leading to 
vulnerability and further suffering. A range of significant palliative care needs was identified with respect 
to patients’ quality of life, functional capacity, symptom burden and preservation of dignity.  
 
Respondents’ quality of life was affected by their high symptom burden, impaired functional 
performance status, large pill-burden and anti-tuberculosis drug side effects. Unemployment, financial 
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insecurity and worry impacted their quality of life. The findings revealed that respiratory and 
gastrointestinal issues were inadequately controlled and visual loss often went unreported to HCPs. 
Financial worries and concerns regarding familial responsibility were prominent. Holistic care was 
absent in the accounts of DR-TB patients interviewed during this study. Respondents expressed a desire 
for a more rewarding therapeutic relationship, having been affected by stigma and lacking a sense of self-
worth and empowerment. 
 
The researcher found literature to support the hypothesis that the higher the symptom burden and the 
lower the quality of life, the greater and more urgent the need for palliative care provision. However, the 
sample size of 28 was insufficient to validate the hypothesis statistically. 
 
6.3   The optimal timing for integrating a palliative care needs assessment in the DR-TB disease 
trajectory 
The WHO definition of Palliative care(49) stated that it should be initiated early in the illness trajectory, 
along with curative therapies that were intended to prolong life. Many patients experienced distressing 
symptoms at the time of DR-TB diagnosis and as a consequence of TB medication side effects. The 
disease trajectory of DR-TB appeared chequered (as Figure 21 illustrated) resulting in the impossibility 
of predicting treatment outcomes or when the patient was nearing the end of life. 
 
Thus, all DR-TB patients should be assessed for their palliative care needs at the time of diagnosis and at 
regular intervals during their illness journey - regardless of whether the end result is cure, treatment 
failure or ultimately death. Regular palliative care needs assessment would ensure that a palliative care 
approach was adopted throughout the disease trajectory. Continuing palliative care needs assessment is 
imperative during routine care and particularly in those whose treatment had failed and had been 
discharged back into the community. 
 
6.4   Response to DR-TB patients’ palliative care needs –ethically and realistically 
HCPs treating DR-TB patients need to be informed of the benefits of providing palliative care. The 
provision of palliative care to DR-TB patients is a “fundamental ethical obligation” (50)  and should be 
appropriate to the expressed and anticipated needs along their disease journey. The needs discovered in 
this study are significant and the requisite response should be proportional - without compromising 
curative therapy. The global, national and local willingness to respond to these needs exposes human 
rights and justice issues. (104)  Palliative care must form part of standard, holistic, patient-centred DR-
TB care at the local, national and global level. 
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Furthermore, the determination of palliative care amongst DR-TB patients should be standardised – and 
thus an assessment tool is required. The questionnaire used in this research study is a modest beginning. 
 
Realistically, those DR-TB patients with fewer, simpler needs qualify for general palliative care 
delivered by their regular HCP practising a palliative care approach and patient-centred care. However, 
more complicated, multi-dimensional needs require the services of a specialist, inter-disciplinary 
palliative care team. 
 
All DR-TB patients should be treated with dignity according to “The Patients’ Charter for Tuberculosis 
Care.” (57)  Thus their needs and human rights ought to be respected and the obligations and 
responsibilities of HCPs and governments recognised. Identifying needs and understanding DR-TB 
patients’ quality of life and burden of disease allows the response of the DR-TB management team to be 
culturally competent and patient-centred; it also directs cost-effective allocation of resources towards 
treatment, adherence and symptom management for the holistic care of patients within their community. 
 
Responding to patients’ palliative care needs also requires a public health approach. Focus should be 
placed on improving patients’ health literacy, empowering patients and addressing stigma. Patients’ co-
morbidities also need to be attended to – such as substance abuse, HIV co-infection and Diabetes. 
 
6.5   Implications of this research study’s findings 
The findings of this research contribute to the knowledge of DR-TB patients’ lived experience and their 
palliative care needs in a setting such as the southern sub-district of Cape Town. All DR-TB patients 
require palliative care. 
 
Figure 21 dispelled the idea that a palliative care approach was only relevant in the last few weeks of life 
and emphasised that it should be integrated actively alongside curative treatment (113)  to provide 
relevant, “culturally sensitive” (20)  and anticipatory support. 
 
6.6    Recommended further studies 
Further research is required to validate the DR-TB palliative care needs assessment tool used in this 
study. A longitudinal study design to determine the evolution of palliative care needs during the DR-TB 
disease trajectory might be more clinically relevant. This study’s questionnaire could also be adapted to 
be used prospectively. Valuable research would be to evaluate the effect of palliative care intervention on 
quality of life and symptom burden in DR-TB patients and to document patient-reported outcomes.(52) 
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More work needs to be done to identify those patients at risk of deteriorating clinically during 
treatment(67) and recognising unmet palliative care needs. Validating the proposed DR-TB disease 
trajectory would be useful for patients, caregivers, educators, HCPs and DR-TB strategists. 
 
6.7   Further challenges of providing palliative care to DR-TB patients 
The over-burdened health care system currently does not allow lengthy consultations with patients and 
their families. A utilitarian approach predominates – often at the expense of the patients’ dignity and 
personhood.(47) 
 
Patients, their families and HCPs need to be educated regarding the intentions and benefits of palliative 
care so that the necessary paradigm shift occurs: palliative care should no longer be thought to be 
nihilistic and contrary to prescribed medical management. A generalised, patient-centred approach needs 
to be reinforced by means of continuing education and practical strategies such as incorporating 
assessment tools and questionnaires into the care process to improve the recognition of symptoms and 
care needs.(52) 
 
Another challenge at national and local level would be the provision of culturally compassionate, end-of-
life care for DR-TB patients  (15,120) – both in the community and in dedicated palliative care facilities. 
These budgetary provisions require political determination.  
 
However, the provision of community-based palliative care is hindered by feared and actual criminal 
violence. Violence limits patients’ access to health care and health care providers’ access to patients. This 
lack of physical safety in the disadvantaged communities of Cape Town should be prioritized on the 
national, regional and local political agendas.  
 
Lastly, palliative care cannot occur if fastidious infection control is not practised and this imposes further 
challenges on budget, personal risk and health care worker willingness to undertake their work of caring. 
 
6.8   Conclusion 
The effects of the “White Plague” still pervade society. The experiences and histories of DR-TB patients 
within the southern sub-district of Cape Town have provided a detailed picture of the suffering that 
results from this infection. To alleviate this suffering and address this growing epidemic, palliative care 
services are urgently required to fulfil the ethical obligations of treating patients with dignity and respect 
throughout their disease trajectory. 
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6.9   Plan for dissemination of findings: 
The research findings will be reported back to the local TB clinic staff via email as well as information 
pamphlets made available for distribution to DR-TB patients in their respective clinics. The Department 
of Health, the City of Cape Town, HPCA, D.P.Marais and Brooklyn Chest hospitals will be emailed a 
copy of the thesis – welcoming discussion regarding the results. Findings will be shared with other 
palliative care colleagues who might be interested in continuing research in this area. It is also planned to 
publish the research findings in a peer-reviewed journal and to submit the study’s abstract to the 49th 








“Measures of suffering have been absent, and so the need for palliative care and pain relief services 
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Declaration on Palliative Care and MDR/XDR-TB(37) 
Geneva, Switzerland, 19 November 2010 
As a group of experts in palliative care and MDR/XDR-TB, we declare: 
1. That access to palliative care for individuals (adults and children) with MDR/XDR-TB is a human 
right and promotes dignity. 
2. That palliative care is an essential component of the provision of care for individuals (adults and 
children) with MDR/XDR-TB, wherever in the world that they are receiving care 
3. That palliative care should be strengthened where being provided, and integrated alongside the 
prevention and treatment of MDR/XDR-TB 
4. That palliative care in the context of MDR/XDR-TB should be integrated into the management of 
MDR/XDR-TB from the time of diagnosis until the patient reaches cure or end of life. The problems 
faced by MDR/XDR-TB patients and families span multiple physical, psychological, social and 
spiritual dimensions. We believe that the existing WHO definition of palliative care is highly 
appropriate for patients with drug-resistant TB. 
5. That palliative care strengthens the Stop TB strategy. 
6. That, as experts on MDR/XDR-TB and palliative care, we are keen to learn from each other. 
7. That we are committed to developing the agenda on palliative care in MDR/XDR-TB, and improving 
access to care, medications, training and capacity building, and collaborating to improve the 
knowledge base through research. 
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Palliative Care and MDR/XDR-TB Integration Meeting, November 18-19, 2010 











Summary of the End TB Strategy (30,122)  
Aim: To end the global TB epidemic 
For the period 2016-2035 
 
Key principles: 
i. Adaptation of the strategy and targets at country level, with global collaboration 
ii. Protecting and promoting human rights, ethics and equity 
iii. Building a strong coalition with civil society and communities 
iv. Government stewardship and accountability, with monitoring and evaluation 
 
Pillars: 
i. Integrated, patient-centred care and prevention. Key components: early diagnosis of TB, 
treatment of all people with TB, collaborative TB/HIV activities, preventive treatment 
ii. Bold policies and supportive systems. Key components: political commitment, engagement of 
communities, universal health coverage, social protection 
iii. Intensified research and innovation. Key components: Discovery, development and rapid uptake 
of new tools, interventions and strategies; research 
 
Targets: 
For 2035: 95% reduction in TB deaths and an 89% reduction in TB incidence, compared with 2015 
For 2030: 90% reduction in TB deaths and an 80% reduction in TB incidence, compared with 2015 
For 2020: 35% reduction in TB deaths and an 20% reduction in TB incidence, compared with 2015 
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Questionnaire (English translation) 
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A study to determine the Palliative Care Needs of Patients with Drug Resistant Tuberculosis in the 
Southern sub-district of Cape Town 
Researcher: Dr Shannon Odell, shannonodell@yahoo.com, 084 556 2778 
Expected time required for completion: 20 minutes 
Introduce yourself to patient in a non-threatening manner:  
Language communicated in: Afrikaans:   English:    isiXhosa:    Other:   
Information sheet given:  
Written consent form signed:  
 
 Date: DD /MM / YY Time: 
1. Age (years): 2. Male:                      Female:  
3. Citizenship:           South African:                           Non-South African:  
4. First language:      Afrikaans:    English:          Xhosa:          Other:  
5. Marital status: Single:   Married:  Partnership/cohabitating:   Divorced:  widowed: 
 Other:  
6. Highest education level: primary school: secondary school:  tertiary education:   none: 
 
7. Setting of interview: Clinic:       Household:  
8. Participant’s dwelling: brick house:   informal settlement:  
9.  Number of windows in dwelling: 
10. Suburb where participant currently resides: 
11. Number of people residing in household (including participant):  
12. Are there other people at your home with TB?: Yes:   No:  
13. Previously diagnosed with TB: Yes :            No:           Uncertain:  
14. When DR-TB was diagnosed: 2017:  2016:  2015:  2014:  2013:  2012:  
before:  
15. When was anti-tuberculosis medication started? 2017:  2016:  2015:  2014:  2013: 
 2012: before 2012:  
16. Are you currently taking anti-tuberculosis medication? Yes:  No:  
17. DR-TB status: defaulter:  treatment failure:  culture converted:  Sputum culture 
positive:  
18. What is your HIV status? Not willing to disclose:  Positive:  Negative:  Unknown: 
  
19. Are you also on anti-retroviral medication?: Yes:   No:  
20. How many tablets/pills do you have to take each day? <10 ; 10-19 ;  >20  
21. Do you have problems taking so many tablets? Yes:  No:  
22. Do you smoke cigarettes? Yes:  No:  
23. Do you use other drugs such as tik, dagga, heroine, cocaine? Yes:  No:  
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24. Have you been hospitalized during the last year? Yes:  No:  
25. Do you receive help from home-based carers? Yes:   No:  
26.  Has having TB affected your ability to work?  Yes:  No:  
27. Functional status/ECOG status: 
Fully active: able to carry on all activities without restriction 0 
 
Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature 
1 
Ambulatory and capable of self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
2 
Capable of only limited self-care: confined to bed or chair 50% or more of waking hours 3 




Ask the patient: 
28. Please rate your pain during the last week: no pain at all 0 
Slight pain 1 
Moderate pain 2 
Severe pain (interferes with 
activities of daily life) 
3 
Very severe pain 4 
Worst/overwhelming pain  5 
29. Have any other symptoms (eg nausea, coughing or 
constipation) been affecting how you feel in the last 
week? 
No symptoms at all 0 
Slight symptoms 1 
Moderate symptoms 2 
Severe symptoms (interferes with 
activities of daily living) 
3 
Very severe symptoms 4 
Overwhelming. The worst 
symptoms imaginable 
5 
30. Have you been feeling worried about your illness in 
the past week? 
Not at all worried 
 
0 
Worried very occasionally 1 
Worried some time 2 
Worried a lot of the time 3 
Worried most of the time 4 
Worried all of the time 5 
31. Over the past week, have you been able to share 
how you are feeling with your family and friends? 
Not at all 0 
Only once 1 
Occasionally 2 
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Fairly frequently 3 
Often 4 
Yes, I’ve talked freely 5 
32. Over the past week have you felt that life was 
worthwhile? 
Not at all 0 
Not very often 1 
Occasionally 2 
Some of the time 3 
Most of the time 4 
Yes, all of the time 
 
5 
33. Over the past week, have you felt at peace? Not at all 0 
Not very often 1 
Occasionally 2 
Some of the time 3 
Most of the time 
 
4 
Yes, all the time 5 
34. Have you had enough help and advice for your 
family to plan for the future? 
None 0 
Very little 1 
For a few things 2 
For several things 3 
For most things 4 
As much as wanted 5 
 
Ask the family member: (Not applicable) 
How much information have you and your family been 
given? 
None 0 
Very little 1 
Some 2 
Quite a lot 3 
A great deal 4 
As much as wanted 5 
How confident does the family feel caring for 
_________? 
Not at all 0 
Not confident about many things 1 
Confident about a few things 2 
Confident about some things 3 
Confident about most things 4 
Very confident 5 
Has the family been feeling worried about the patient 
over the last week? 
Not at all worried 0 
Worried very occasionally 1 
Worried some of the time 2 
Worried a lot of the time 3 
Worried most of the time 4 




The following questions ask about symptoms in the last week. Please rate how you were bothered by 
each symptom. (Mark with an X) 
 
0= I do not have this symptom 
1= I have this symptom, it doesn’t bother me 
2= I have this symptom, it bothers me a little 
3= I have this symptom, it bothers me 





 0 1 2 3 4 
35.  difficulty falling or staying asleep      
36.  feeling dizzy or light-headed      
37.  fatigue or loss of energy      
38.  pain, numbness or tingling in the hands or feet      
39.  nausea or vomiting      
40.  diarrhoea      
41.  loss of appetite      
42.  shortness of breath      
43.  coughing up blood      
44.  skin problems, such as rash, dryness or itching      
45.  ringing in your ears or loss of hearing      
46.  joint pains      
47.  ongoing pain at injection sites      
48. confusion or trouble remembering      
49. tremors, shaking or fits      
50. feeling sad, down or depressed      
51. feeling suicidal      
52. feeling hopeless      
53. feeling anxious or scared      
54. having remorse or regret      
55. feeling like you’re not coping      
56. feeling stigmatized by family, relationships are 
limited 
     
57. feeling stigmatized by community or discriminated 
against 
     
58. feeling stigmatized by health care professionals, 
abandoned 
     
59. feeling isolated and lonely      
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60. worried about finances/money      
 










63. Distress protocol required:  Because:________________________________________________ 
Patient referred to: ____________________________________________________________________ 
 
Reassure participant that information given will remain confidential:  
Enquire whether the participant has any further questions or comments relating to the research:  
Thank the participant for their time and input:  
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‘n Studie om die Palliatiewe Versorgingsbehoeftes van Pasiënte met Medikasie Weerstandige-
Tuberkulose (DR-TB) in die Suidelike subdistrik van Kaapstad te bepaal. 
Dr Shannon Odell; shannonodell@yahoo.com; 0845562778 
Verwagte tyd wat nodig is vir die voltooiing: 20 minute 
Stel jouself aan die pasiënt bekend op ‘n nie-bedreigende manier:  
Taal waarin daar gekommunikeer is: Afrikaans:  Engels:   isiXhosa:    Ander:   
Inligtingsbladsy gegee:  
Ingeligte toestemmingsdokument geteken:   
 
 Datum: DD/MM/JJ         Tyd: 
1. Ouderdom (jare): 
 2. Manlik:                      Vroulik:  
3. Burgerskap:        Suid-Afrikaans:                          Nie-Suid-Afrikaans:  
4. Eerste taal:      Afrikaans:   Engels:         isiXhosa:         Ander:  
5. Huweliksstatus: Enkel:  Getroud: Vennootskap/woon saam:  Geskei:  
Weduwee/wewenaar: Ander:  
6. Hoogste onderwysvlak: laerskool: hoërskool: tersiëre onderwys:  geen:  
7. Omgewing van onderhoud: Kliniek:     Tuis:  
8. Deelnemer se behuising: baksteenhuis:  informele behuising:  
9. Hoeveel vensters in die huis? 
10. Woongebied waarin die deelnemer tans woon:  
11. Aantal mense inwonend in die huishouding: 
12. Is daar mense in die huishouding wat tans geïnfekteer is met TB:  
13. Voorheen gediagnoseer met TB: Ja:  Nee:  Onseker:  
14.Wanneer is DR-TB gediagnoseer? 2017: 2016: 2015: 2014: 2013: 2012:  
vroeër:   
15. Wanneer is U met TB medikasie begin? 2017: 2016: 2015: 2014: 2013:  
2012: voor 2012:  
16. Gebruik u tans TB (anti-tuberkulose) medikasie?   Ja: Nee:  
17. DR-TB status: droster (defaulter):   
nalatigheid in verband met medikasie to neem (treatment failure):  kulturele oortuigings :    
sputum culture positive:  
18. Wat is u HIV status? Nie bereid om saam te deel nie: Positief: Negatief: Onbekend:   
19. Gebruik u tans ook ARVs (anti-retrovirale medikasie)?: Ja:  Nee:  
20.  Hoeveel pille (tablette) moet u elke dag neem? <10 ; 10-19 ; >20  
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21.  Vind u dit moeilik om al die pille (tablette) te neem? Ja:  Nee:  
22. Rook u sigarette? Ja:  Nee:  
23. Gebruik u ander dwelms soos tik, dagga, heroine of kokaiene?  Ja:  Nee:  
24. Is u gehospitaliseer gedurende die afgelope jaar?  Ja:  Nee:  
25. Ontvang u hulp van tuisversorgers?:             Ja:  Nee:  
26.  Vandat jy TB het, is daar enige probleme om jou werk te doen? Ja:  Nee:  
 
27. Funksionele status/ ECOG status:  
Ten volle aktief: in staat om alle aktiwiteite, sonder beperkings uit te voer. 0 
 
Beperk ten opsigte van uitpeuttende, fisiese aktiwiteite, maar kan loop/is beweeglik en is in staat 
om ligte werk of werk van ‘n sittende aard te doen. 
1 
Kan loop/beweeglik en in staat tot selfversorging, maar nie in staat om enige werksaktiwiteite 
uit te voer nie. Op en aan die gang vir meer as 50% van die dag. 
2 
Slegs in staat tot beperkte selfversorging: 50% of meer van tyd bedlêend of beperk tot ‘n stoel  3 
Heeltemal gestremd; nie in staat tot enige selfversorging nie; heeltemal bedlêend of beperk tot ‘n  
Stoel 
4 
(Oorlede  5) 
 
APCA African POS: 
28. Evalueer asb u pyn gedurende die afgelope week: Geen pyn 0 
Effense pyn 1 
Matige pyn 2 
Ernstige pyn (beperk alledaagse 
aktiwiteite) 
3 
Baie ernstige pyn 4 
Die ergste/oorweldigende pyn 5 
29. Het enige ander simptome (bv naarheid, gehoes of 
hardlywigheid) u gemoedstoestand beïnvloed die afgelope 
week? 
Geen simptome 0 
Ligte simptome 1 
Matige simptome 2 
Ernstige simptome (beperk 
alledaagse aktiwiteite)  
3 
Baie ernstige simptome 4 
Oorweldigend. Die ergste 
simptome denkbaar 
5 
30. Was u die afgelope week bekommerd oor u siekte? Glad nie bekommerd nie 0 
So nou en dan bekommerd 1 
Soms bekommerd 2 
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Dikwels bekommerd 3 
Meeste van die tyd bekommerd 4 
Die heeltyd bekommerd 5 
31. Was jy die afgelope week in staat om jou gevoelens met 
jou familie en vriende saam to deel?  
Glad nie 0 
Slegs een keer 1 
So nou en dan 2 
Redelik gereeld 3 
Dikwels 4 
Ja, ek het vrymoediglik gepraat  5 
32. Het jy die afgelope week ervaar dat die lewe die moeite 
werd is? 
Glad nie 0 
Nie baie dikwels nie 1 
So af en toe 2 
Somtyds 3 
Meeste van die tyd 4 
Ja, die heeltyd 5 
33. Het jy die afgelope week vrede in jou gemoed ervaar? Glad nie 0 
Nie baie dikwels nie 1 
Af en toe 2 
Somtyds 3 
Meeste van die tyd 4 
Ja, die heeltyd 5 
34. Het jy voldoende hulp en advies ontvang, sodat jou 
familie vir die toekoms kan beplan? 
Geen 0 
Baie min 1 
Met ‘n paar goed/items 2 
Met verskeie goed/items 3 
Met meeste goed/items 4 
Genoegsame informasie 5 
 
Van hoeveel inligting is jy en jou familie voorsien? Geen 0 
Baie min 1 
Sommige 2 
Nogal baie 3 
Besonder baie 4 
So veel as nodig 5 
Hoe seker voel jou familie oor die versorging van ___________? Glad nie 0 




Seker oor ‘n paar goed/dinge 2 
Seker oor sommige goed/dinge 3 
Seker oor meeste goed/dinge 4 
Baie seker 5 
Was die familie bekommerd oor die pasiënt gedurende die 
laaste week? 
Glad nie bekommerd nie 0 
So nou en dan bekommerd 1 
Soms bekommerd 2 
Dikwels bekommerd 3 
Meestal bekommerd 4 
Die heeltyd bekommerd 5 
  
Simptoom-las: 
Die volgende vrae gaan oor simptome oor die afgelope 7 dae (een week). Evalueer asb hoeveel elke betrokke 
simptoom jou gepla het. (Merk met ‘n X) 
 
0= Ek het nie die simptoom nie. 
1= Ek het die simptoom, (maar) dit pla my nie. 
2= Ek het die simptoom; dit pla my ‘n bietjie. 
3= Ek het die simptoom; dit pla my. 




 0 1 2 3 4 
35.  Raak moeilik aan die slaap of bly nie aan die slaap nie      
36.  Voel duiselig of lighoofdig      
37.  Moegheid of gebrek aan energie      
38.  Pyn, gevoelloosheid of ervaar prikkelgevoel in hande of voete      
39.  Naarheid of gooi op      
40.  Diaree      
41. Geen eetlus      
42.  Kortasem      
43.  Hoes bloed      
44.  Velprobleme soos uitslag, droogheid of gejeuk      
45.  Gesuis/gefluit in ore of gehoorverlies      
46.  Gewrigspyne      
47.  Voortdurende pyn in areas wat ingespuit is      
48. Verwarring of sukkel om te onthou      
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49. Bewerasie of stuiptrekkings      
50. Voel hartseer, af of depressief      
51. Selfmoord neigings      
52. Voel hulpeloos/sonder hoop      
53. Voel angstig of bang      
54. Ervaar selfverwyt of spyt      
55. Voel of jy nie in beheer is nie.      
56. Voel verstoot deur familie; verhoudings is beperk      
57. Voel verstoot deur gemeenskap of word teen gediskrimineer      
58. Voel verstoot deur professionele gesondheidssorg persone      
59. Voel geïsoleerd en eensaam      
60. Voel bekommerd oor finansies/geld      
 










63.  Nood protokol benodig: Omdat:________________________________________________ 
 
Pasiënt is verwys na: ________________________________________________________________ 
Verseker deelnemer weereens dat gegewe inligting vertroulik sal bly:  
Doen navraag of die deelnemer enige verdere vrae of opmerkings het, wat verband hou met die 
navorsing.:  
Bedank die deelnemer vir sy/haar tyd en insette:  
 










 Questionnaire (isiXhosa translation) 
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U phando ngokufuna u kwazi nge zidingo zesigulane e sine Drug Resistant Tuberculosis eSouthern sub-
district of Cape Town 
Ophandayo Qgirha u Shannon Odell, shannonodell@yahoo.com, 084 556 2778 
Ixesha e lilinganiselweyo loku qhiba: 20 minute 
Zazise kusigulane nge ndlela engamothusiyo:  
U lwimi lwa sekhaya: Afrikaans:   English:    isiXhosa:    Other:   
Iphepha lolwazi nge sazi si vumelwano:  
Um thathi ngxaxheba u xelelwe nge sazi si vemelwano :   
 
 Date: DD /MM / YY     Time: 
1. Age (years)/iminyaka yakhe: 
2. indoda (M) :          Intombi (F):  
3. Ungumi waphi:  South African/ungumi walapha:      Non-South African/ ungumi wanga 
phandle:  
4. ulwimi lwenkobe:      isibhulu:    Isingesi:          Xhosa:          ezinye:  
5. Marital status: andi tshatanga:   nditshatile:  Ndiyahlalisana:   ndo hlukene 
nomlingani wam:  Umhlolo/umhlolokazi  ezinye:  
6. I banga eli phezuli owali phumelelayo esi kolweni:  Isikolo samabanga aphantsi:  
Isikolo samabanga a phezulu:    nDyunivesiti:    zange ndalibeka esikolweni:  
7. Lwe nzelwa phi oludliwano ndlebe Clinic:       endlini:   
8. Umthathi nxaxheba uhlala endlini enjani: indlu yesi tena     ityotyombhe:  
9.  Zingaphi ifestile endlwini: 
10. Isi xeko apho umthathi ngxaxheba ehlala khona: 
11. Banga phi abantu abahlala nom thathi mgxaxheba: 
12. Banga phi abantu abahlala nom thathi mgxaxheba abanale ithsolongwane ye TB: 
13. wakhe wa nayo ngaphambili I TB: Ewe      hayi:        andi qhinisekanga:  
14. I qale nini ukuku phatha le ntsholongwane ye DR-TB: 2017: 2016:  2015:  
2014:   2013:  2012:  Ngaphambili:   
15. wa qala nini uku sebenzisa ama pilisi e anti-tuberculosis? 2017: 2016:  2015:   
2014:  2013:  2012:  Nga phambili:  
16. Ingaba u thatha ipilisi ze anti-tuberculosis? Ewe:  Hayi:  
17. Si yintoni is simo sakho se DR-TB: oyeke unyango phambi kwe thuba:   
ukupheza konyango:  ukuphela kwentsholongwane:  
18. Si yintoni isimo sakho se HIV?  Siyifihlo yam:   ndinayo:  andinayo:  andisazi:   
19. Ingaba u thatha ipili I anti-retroviral? Ewe:   Hayi:   
20. Zingaphi I pillisi ozithathayo nge mini? <10  10-19   >20  
21. Ingaba ufumana ubunzima Ngo ku thatha I pillisi ezinintsi ka ngaka?  Ewe:    Hayi:   
22. Ingaba uyatshaya icuba? Ewe:    Hayi:   
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23. Ingaba usebenzisa iziyobisi? I tiki, intsango, heroine okanye I cocaine?  Ewe:   Hayi:  
24. Ubukhe wa lala esibhedlela kulo nyaka uqhithileyo? Ewe:    Hayi:   
25. Ingaba uyalifumana uncedo kubantu aba zisa uncedo ezidlini? Ewe:    Hayi:   
26.  Ingaba unayona ingxeki yokusebenza kube unesisisfo sephepha?    Ewe:   Hayi:  
 
27. Izinga lokwazi ukuzenzela 
Uyakwazi ukuzenzela 0 
Uyanzinyelwa ngumsebenzi ofuna amandla kodwa u ya kwazi uku hambha, no kwenza  
Imisebenzi enga funi mandla 
1 
uya kwazi ukuzihambela, kwaye uya kwazi ukuzonga uthi elapha abe engaphaya I xesha  
elingange 50% emini 
2 
uyazama kekodwa ukuzonga kodwa uyo yisakala.uhleli esebhedini okanye ehleli esitulweni I  
xesha elingange 50% emini 
3 
Akakwazi tu ukuzihambela: akakwazi tu ukuzonga:ubophelelekile e bhedini okanye esitulweni 4 
(uswelekile 5) 
 
APCA African POS: 
28. ndicela undi xelele ngobu ngaka nani bentlungu  
zakho kule veki /nyaka uphelileyo 
akukho zinhlungu 0 
zikhona kancinci 1 
Ziya vakala wethu  2 
Zibuhlungu kwaye zindi sebenzisa  
Kabuhlungu 
3 
Zibuhlungu kakhulu 4 
Ziyandongamela intlungu 5 
29. Ingaba ezinye ze zi mphawu beziku phatha, 
kulonyanka/veki uqhithileyo? 
(ukukhonyuluka,khohlela okanye ukuqhinwa kwe 
sisu? 
Hayi andinazo ezi mphawu 0 
Zikhona,kodwa hayi ngamandla 1 
Zikhona kodwa ziya nyamezeleka 2 
Zikhona ngamandla ezimphawu, 
andikwazi uku sebenza kakuhle 
3 
Ziyandihlupha ka khulu ezimphawu 4 
Ziya ndonga mela  5 
30. Ingaba ubuziva ukhathazekile ngesi gulo sakho  
kulo nyaka uqhithileyo? 
Hayi bendinga khatha zekanga 0 
Be ndikhatha zeke kancinci 1 
Be ndikhe ndikhathazeke ngamanye  
ama xesha 
2 




Be ndikhathazeke kakhulu amaxesha  
amaninzi 
4 
Be ndikhatha zekile ngawo wonke  
ama xesha 
5 
31. Kulonyaka uqhithileyo,ubukhe wakwazi u ku  
xelela usapho lwakho ngendlala oziva ngayo nge si  
gulo sakho? 
Hayi 0 
ndaba xelela kakanye 1 
ndakhe ndaba xelela 2 
ndi ya ba xelela 3 
ndi ba xelela oko oko 4 
Ewe, ndi thetha ngo ku khulilekileyo  
Nabo 
5 
32. kwezi veki zigqithileyo ubukhe wabubona ubomi  
bumyoli/ bumnandi?  
Hayi 0 
hayi kakhulu 1 
Nga manye amaxesha 2 
Nga manye amaxesha 3 
Ngama xesha amaninzi 4 
Ewe, ngawo wonke amaxesha 5 
33. kule veki I phelileyo,ingaba ubuziva u no xolo  
empheulweni wakho 
Hayi 0 
Hayi ngama xesha amaninzi 1 
Nga manye ama xesha 2 
Nga manye ama xesha 3 
Ngama xesha ama ninzi 4 
Ewe ,ngawo wonke ama xesha 5 
34. Lungaka nani uncedo,ne ngcebiso enizi fumaneyo, 




Zi khona endinazo 2 
ndi nazo eziza ku nceda kwi zinto  
ezimbalwana 
3 
ndi nazo,ezizakundinceda kwi zinto  
ezininzi 
4 
Si nazo kangangoko sizi funa 5 
Not applicable 
Lungaka nani u lwazi ,eluninikiwe wena no sapho 
 Lwakho? 
Alukho 0 




Kanga ngoku sili funa 5 
Lu zi thembhe ka ngaka nani u sapho lwakho, ngo  
konga wena? 
Aluzi thembhanga tu 0 
aluzi thembhanga nge zinto ezininzi 1 
Luzi thembhe ngezinto ezimbalwa 2 
Luzi thembile ngezinye zezinto 3 
Luzi thembile ngezinto ezininzi 4 
Luzithembhe ka khulu 5 
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Ingaba usapho lwakho ,be lukhathazekile kule veki  
iphelileyo ngawe? 
Bebenga khathazekanga tu 0 
bebe khathazeke nje 1 
bebe khathazekile ngamanye ama 
xesha 
2 
bebe khathazekile ngama xesha 
amaninzi 
3 
bebe khathazekile ngama xesha 
amaninzi 
4 
bebe khathazekile ngama xesha wonke 5 
 
Ingaba ziya ku khathaza imphawu zesisi gulo 
Le mibuzo I landelayo ,I buza nge mphawu zakule nyanga I qhithileyo. Ndicela u bonise ukuba be zi ku  
khathaza kangaka nani na I mpawu zesisi gulo 
 
 
0= Andinazo imphawu 
1= ndinazo ezi impawu kodwa azindi khathazi 
2= ndinazo ezi impawu, ziyandi khathaza ka ncinci 
3= Ndinazo ezi impawu, ziyandi khathaza 
4= Ndinazo ezi impawu, ziyandi khathaza ka khulu 
 0 1 2 3 4 
35.  awu kwazi ku lala okanye ukunga lali      
36.  uphathwa sisi yezi okanye u kujikelezwela yi ntloko      
37.  uku dinwa okanye uku phelelwa nga mandla      
38.  intlungu,ukuba ndindisholo kwezandla okanye inyawo      
39.  uku khonyuluka okanye ukugabha      
40.  ingaba uhanjiswa sisusu      
41. ukungabi namandla      
42.  uku phelelwa ngu moya okanye uku phefumla nzima      
43.  khohle la I gazi      
44.  ingxaki no lusu,I rwayibhane,uku xweba kolusu,uku rhawuzelela ko 
 lusu 
     
45.  uku ngeva kakuhle      
46.  Intlungu zemi phakathi      
47. intlungu kule ndawo u jove kuyo      
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48. u ku dideka okanye uku libala      
49. ukungcangcazela,uku xhuzula      
50. uziva umoya wakho ungonwabanga/udangele/uphantshi      
51. I ngaba vzuva ufuna ukuzi bulala ngamanye ama xesha?      
52. uziva uphelelwe li thembha      
53. Uziva wothukile okanye u so yika      
54. Uziva u zi so la      
55. Uziva ingathi aku nyamezeleki      
56. Uziva uhlelelekile lu sapho lwakho,awunaba lingani      
57. Uziva u hlelelekile kwi lokisi yakho      
58. Uziva u hlelelekile ngabantu bakwezempilo      
59. Uziva u wedwa,      
60. Ingaba ukhathazekile nge mali      
 








63. ingaba iyamcaphukisa imibuzo:  kuba: _____________________________________________ 
isiguli sithunwe ngu:__________________________________________________________________ 
Mthembise umthathi ngxaxheba ukuba,oluphando luzakuba yifihlo:   
Buza u kuba umthathi ngxaxheba akanazo na yena eyakhe imibuzo okanye into afuna uku yithetha 
ehambhelana nolu phandolwazi?  
Bulela umthathi nxaxheba nge xesha lakhe nange ngalelo lakhe:   
 










Information sheet for trial participants (English translation) 
 111 
A study to determine the Palliative Care Needs of Patients with Drug Resistant Tuberculosis in the 
Southern sub-district of Cape Town 
Thank you for thinking about taking part in this research study.  
 
This information sheet will give you an idea of what it will involve, so please read it carefully. It is 
available in English, Afrikaans and isiXhosa, and the interviewers will read it to you if you so wish. 
 
Feel free to ask the interviewer any questions if you’re unsure about anything. Please don’t feel pressurized 
to agree straight away, rather be sure you understand fully what will be asked of you, and take time to 
discuss with a friend or family member if you need to. The interview could then be arranged at another, 
more suitable time.  
 
Your taking part in this research is completely voluntary and unconditional, which means that if you’d 
rather not answer the questions or wish to stop during the interview, that is your choice, and it will not be 
held against you or affect the care you will receive by the doctors, nurses or counselors involved in your 
current and future management. This gives you the opportunity to be completely honest in your 
answers. Very importantly, should you prefer not to participate, your ongoing care will not be 
affected. 
 
Who is doing this research? 
Dr Shannon Odell, who is a medical doctor, studying palliative medicine. She, along with the help of a 
volunteer or counselor/s will be conducting this research- speaking to patients and asking the questionnaire. 
The volunteer or counselor may be known to you already, and have been involved in your care and follow-
up before. This relationship will not change by your participating or not participating in this 
research, however you may find that your relationship with the volunteer or counselor is 
strengthened.  
 
Why is this research being done? 
This study wants to understand how DR-TB affects you-the symptoms that are difficult for you and the 
quality of life you are challenged with.  
 
Why is this research important? 
This research is important because little is known of what it feels like to have DR-TB in this community of 
Cape Town. It is important to find out how many patients are struggling with similar symptoms, and how 
severely these impact on the quality of your lives. This knowledge is vital in the planning of better health 
service provision and support for those affected by DR-TB. 
 
What information is being collected? 
Questions regarding your quality of life and the physical, psychological, social, financial and spiritual 
symptoms you experience will be asked from a questionnaire and completed by the interviewer.  
 
What will happen to the results of this questionnaire? 
All the answers from the questionnaires will be collected, kept safe and confidential and then analysed. 
Your name will not appear on this analysis, and all your answers will remain confidential. That means that 
no matter what you say, it will not point back at you, and your honest answers will not affect your 
current care or future management. The final results and analysis will be presented to the Department of 
Health, the Western Cape Government, the City of Cape Town and other interested parties or possible 
donors. By sharing this information I hope to highlight the need for providing better care for all DR-TB 
patients in the community and urge for more funding to be available to deliver this care. 
 
How long will this information be kept? 
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Your answers will be stored until all questionnaires have been collected, studied and the results have been 
summarized and written into a thesis document. After the presentation of the findings all the answers will 
be deleted. 
 
With whom will these results be shared? 
Dr Odell and the volunteer/counselors involved in asking the questionnaire will share information if there 
are any problems experienced in the process of collecting the information. This information will be 
confidential, with the focus on what is reported and not who reported the information. This 
information will also be discussed with Dr Odell’s supervisor and the assistant helping with the analysis. 
The final results will be submitted as part of the Master of Philosophy thesis to the University of Cape 
Town in the last quarter of 2017. Further sharing of information is planned with the Department of Health, 
the Western Cape Government, the City of Cape Town and other interested parties or possible donors. 
Results will also be available at the local clinic for any DR-TB patients in the community whether they 
have participated in the questionnaire or not. 
 
What will it mean for you? 
The questionnaire will take approximately 20-30 minutes of your time, and there will be no payment. 
 
What if the questions are too upsetting? 
You may stop the interview at any time and change your mind about carrying on. Your taking part is 
voluntary and you will not be discriminated against if you find it too upsetting to continue. The person 
interviewing you might then suggest referring you to the clinic for further help or care. 
 
What does “informed consent” mean? 
Before giving your permission to be included in this study, it is very important to be aware of what that 
means. The aim of the consent form is to give you further information on the study, that you understand 
what will be asked of you and to make sure you can make your own decision based on correct, honest 
information, without feeling forced to do so. 
 
If you have any further queries about this research study, please contact: 
Dr Shannon Odell 
084 556 2778 
shannonodell@yahoo.com 
 
Should you have any queries regarding your rights and welfare participating in this research, please contact 
the UCT Research Ethics Committee: 
Mrs Lamees Emjedi 
Research Ethics Committee Administration Supervisor 
E52 Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
021 406 6338 
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 ‘n Studie om die Palliatiewe Versorgingsbehoeftes van Pasiënte met DR-TB in die     
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     Suidelike sub-distrik van Kaapstad te bepaal 
 
Dankie vir u gewilligheid om deel te neem aan hierdie navorsingsstudie. 
 
Hierdie inligtingsbladsy sal u ‘n aanduiding gee wat die studie behels. Lees dit asb sorgvuldig deur. Dit 
is beskikbaar in Engels, Afrikaans en isiXhosa en die onderhoudvoerders kan dit vir u lees, indien u dit 
verkies. Rig gerus enige vrae aan die onderhoudvoerder, as u onseker is oor enigiets. Moet asb nie 
verplig voel om dadelik in te stem nie. Indien nodig, maak eerder seker u verstaan wat van u verwag 
word en neem tyd om dit met ‘n vriend of familielid te bespreek. Die onderhoud kan dan gereël word op 
‘n meer geleë tyd.  
 
U deelname aan hierdie navorsing is heeltemal vrywillig en onvoorwaardelik, wat beteken dat as u 
liewer nie die vrae wil beantwoord nie en verkies om te onttrek tydens die onderhoud, dit nie teen 
u gehou sal word of die behandeling beïnvloed wat u tans deur die dokters, verpleegsters of 
beraders wat betrokke is by u huidige of toekomstige behandeling ontvang nie. Dit gee u die 
geleentheid om heeltemal eerlik te wees met u antwoorde. Dis belangrik om te onthou dat indien u 
verkies om nie deel te neem nie, u voortdurende versorging nie geraak sal word nie. 
 
Wie doen hierdie navorsing? 
Dr Shannon Odell, ‘n mediese dokter, wat tans in palliatiewe medisyne studeer. Sal met behulp van ‘n 
vrywilliges of berader/s die navorsing behartig, met die pasiënte gesels en die vraelys hanteer. Die 
vrywilliges en berader mag reeds aan u bekend wees en was dalk vroeër betrokke by u versorging en 
opvolg. Hierdie verhouding sal nie verander deur u deelname/nie-deelname aan hierdie navorsing nie. U 
mag selfs vind dat U verhouding met die betrokke berader sterker word. 
 
Waarom word hierdie navorsing gedoen? 
Hierdie studie probeer bepaal hoe DR-TB u affekteer, die simptome wat vir u moeilik is (om te hanteer) 
en die uitdagings wat die kwaliteit van U lewe beïnvloed. 
 
Hoekom is hierdie navorsing belangrik? 
Hierdie navorsing is belangrik omdat baie min bekend is van hoe dit voel om DR-TB te hê in die 
gemeenskap van Kaapstad. Dit is belangrik om uit te vind hoeveel pasiënte met dieselfde simptome 
sukkel en hoe ernstig die impak is op u lewenskwaliteit. Hierdie kennis is baie belangrik in die 
beplanning en voorsiening van beter gesondheidsdienste vir diegene met DR-TB. 
 
Watter tipe inligting word versamel? 
Vrae sal op die vraelys gevra word oor u lewenskwaliteit, sowel as die fisiese simptome, emosiönele, 
sosiale, finansiële en geestelike behoeftes wat u ervaar en dan voltooi word deur die onderhoudvoerder. 
 
Wat gaan gebeur met die uitslae van die vraelys? 
Al die antwoorde op die vraelys sal versamel word, veilig en vertroulik bewaar word en dan geanaliseer 
word. U naam sal nie op die analise verskyn nie en al u antwoorde sal vertroulik bly. Dit beteken dit 
maak nie saak wat u antwoord nie, dit sal nie na u terugverwys word nie en u earlike antwoorde sal nie u 
huidige of toekomstige versorging en hantering beïnvloed nie. Die finale uitslae en analise sal aan die 
Departement van Gesondheid, die Wes-Kaapse en Kaapstad Regering en ander belangstellende of 
moontlike skenkers aangebied word. Deur die deel van hierdie inligting, hoop ek om die nood/behoefte 
vir beter versorging aan alle DR-TB pasiënte in die gemeenskap uit te lig en te pleit vir groter 
befondsing om hierdie diens te lewer. 
 
Hoe lank sal die inligting bewaar word? 
U antwoorde sal gebêre word totdat al die vraelyste ingesamel, bestudeer en die uitslae opgesom en in ‘n 
tesis opgeteken is. Na die aanbieding van die bevindinge sal al die antwoorde uitgewis word. 
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Met wie gaan hierdie uitslae gedeel word? 
Dr Odell en die vrywilliges/beraders betrokke in die vrae van die vraelys sal inligting deel indien daar 
enige probleme ervaar word tydens die insameling van inligting. Hierdie inligting is vertroulik, met die 
fokus op wat gerapporteer is en nie wie die inligting gerapporteer het nie. Hierdie inligting sal ook 
bespreek word met Dr Odell se toesighouer en die wat help met die analise. Die finale uitslae sal 
aangebied word as deel van die Meesters in Filosofie tesis aan die Universiteit van Kaapstad, tydens die 
laaste kwartaal van 2017. Verdere deel van inligting word beplan met die Departement van Gesondheid, 
die Wes-Kaapse regering, die stad, Kaapstad en ander belangstellende partye of moontlike skenkers. 
Uitslae sal ook beskikbaar wees by die plaaslike kliniek vir enige DR-TB pasiënte in die gemeenskap, of 
hul deelgeneem het of nie. 
 
Wat sal dit vir u beteken? 
Die vraelys sal ongeveer 20-30 minute van u tyd in beslag neem en daar is geen vergoeding nie. 
 
Wat gebeur indien die vrae te ontstellend is? 
U mag die onderhoud enige tyd staak en van besluit verander om voort te gaan. U deelname is 
vrywillig en daar sal nie teen u gediskrimineer word, indien U dit te ontstellend vind om voort te 
gaan nie. Die onderhoudvoerder mag voorstel om u na die kliniek te verwys vir verdere hulp of 
ondersteuning.  
 
Wat beteken “ingeligte toestemming”? 
Voordat u toestemming gee om ingesluit te word in hierdie studie, is dit baie belangrik om bewus te 
wees oor wat dit beteken. Die doel van die toestemmingsvorm is om aan u verdere inligting te gee oor 
die studie, sodat u verstaan wat van U gevra sal word en om seker te maak dat u, u eie besluit kan maak, 
gebasseer op korrekte, earlike inligting, sonder om verplig te voel om dit te doen. 
 
Indien u enige verdere navrae oor hierdie navorsingsstudie het, kontak asb: 
Dr Shannon Odell 
084 556 2778 
shannonodell@yahoo.com 
 
Indien u enige navrae oor u regte en welvaart het, terwyl u deelneem aan hierdie navorsing, kontak asb: 
Die UK Navorsings – Etiese – Komitee 
Mev Lamees Emjedi 
Navorsing(s) Etiese Komitee Administratiewe Toesighoer 
E52 Kamer 24, Ou Hoofgebou, Groote Schuur Hospitaal, Observatory 
021 406 6338 
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I phepha lolwazi ngom thathi nxaxeba kolu phandulwazi 
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U phando ngokufuna u kwazi nge zidingo zesigulane e sine Drug Resistant Southern sub-district of Cape 
Town 
 
Enkosi ngoku cinga uku thatha inxaxheba kolu phandolwazi. Eli phepha lolwazi lizakunika incazelo 
malunga nga le mibuzo ozo kuyi buzwa, nceda uyifunde nge ndlela e cacileyo, Le mibuzo ikho nge 
lwimi lwe si Ngisi,Afrikaans nange si Xhosa, cela umbuzi mibuzo akafundela xa ufuna. Khululeka 
umbuze umbuzi mibuzo nawuphi na umbuza xa kukho into ongayi qondiyo.ungazivi unyanzelekile uku 
phendula, Qala ngo ku fundisisa lemibuzo kugala. Kwaye u thathe ixesha lakho, ukhe u thethathethane 
nomhlobo okanye umdeni wakho malunga nalemibuzo. Oludliwano ndlebe lunge nzeka ngelinye 
ixesha, I xesha ela nelisa wena. Yazi ukuba awu nyanzeliswa ukuba u thathe ingxagxe ba kolu 
phando lwazi, isi qhibo so. Ukuba uqhibe ekubeni unga thathi inxaxheba, yazi ukuba u longiwo 
lwakho aluzuku phazamiseka, luzaku qhubeka njenge siqhelo. Eli lithuba lokuba uphendule 
ngokunyanisekileyo, kubalulekile ukuba wazi ukuba xa uziva ungathandi ukuvakalisa izimvo 
zakho, oko akunakuchaphazeleka ubudlelwane bakho nobethu. 
 
Ngu bani lo wenza o lu phandulwazi? 
U qhira Shannon Odell,No mncedisi wakho/izakube ingabo aba qhuba olu thetho thethwano malunga no 
lu phando lwazi.U mncedisi izakuba ngumtu osele umqhelile,obesebenzisana nawe encedisana nawe 
esigulweni sakho. U budlelwana benu abusoze butshintshe ngexa yakuba uthathe inxaxheba okanye 
ugqibe ekubeni ungayi thathi inxaxheba. 
 
Lwe nzelwa ntoni olu phandu lwazi? 
Lincedisa eku caciseni ezinye zemphawu zesisi gulo no kwazi ibanga le mpilo elinga philwa ngum guli. 
 
Kutheni lubalulekile alu phando lwazi? 
Olu phandolwazi lubaluleke ngoba luncinci ulwazi olwaziwayo malunga nesisi gulo I DR-TB kule 
ndawo esikuyo apha e Kapa. Ku balulekile ukwazi ukuba zinga phina izigulani ezikhathazwe zimphawu 
ezifanayo zesisi gulo,kwaye zilwenza lube njani uzinga lwabo lo kuphila ne sisi gulo. Olulwazi 
lubalulekile xana umzi wezempilo ehlela indlela yoku jonga izigulane Ze DR-TB. 
 
lo luphi o lu lwazi lufunwayo? 
Kolu dliwano ndlebe u zaku buzwa malunga nobunjani be mpilo oyiphilayo nesisi gulo, si kuphatha 
njani emzimbheni,emoyeni, ubudlelwane bakho nabanye abantu bu caphazelekenjani, nase malini 
kwakunye nemphawu ezikuphathayo zesisi gulo. 
 
Yintoni ezakwenzeka kwizi phumo zoludliwano ndlebe? 
Zonke iziphumo ziza ku gcinwa, kwindawo ekhuselekileyo. I gama lakho liza kuhlala liyi mfihlo, ne 
mphendulo zakho ziza ku khuselwa. Lento ke I thatha ukuthi, imphendulo zakho azisoze zaziwe ukuba 
zezakho, ukunyaniseka kwakho ekuphenduleni lemibuzo akusoze ku phazamise indlela ohoyeke ngayo. 
E pheleleyo incukaca izakunikwa, iDepartment of Health. Sibabonise ukuba bazazi ifuno zazi gulane, 
banduleke ukuncedisa ngoncedo oluzakunceda izigulane. 
 
Lu za Ku thatha I xesha elingakanani olu lwazilugciniwe? 
Imphedulo zakho zoludliwanondlebe zizakugcinwa kuze kufumaneke zonke imphedulo. Xa sezi 
ncwangci siwe zonke, ulwazi ne ngcazelo ifumanekile, imphendulo zakho ziza ku cinwa ke. 
 
 
Ziza ku boniswa bani ezizi phumo? 
Nge li xesha zi qhokelelwa zonke ezi ncukanca, Dr Odell kwa kunye nomncedisi wakhe bazaku 
lencukaca izaphindwa I bonwe ngum phathi ka Dr Odell, xa e ncedisa ekuhloleni yonke incukaca ethe 
yafumaneka. E pheleleyo incukaca izakunikwa, I University of Cape Town, phakathi kulo nyaka uzayo 
2017. Banalo igunya loku bona iziphumo zolu phandulwazi, I ziphumo zolu phandulwazi zi za 
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kuumaneka kwi clinic Ye DR-TB nabantu aba gula yi MDR-TB baza kwazi ukuzi bona iziphumo xabezi 
funa. 
 
Zakunceda ngantoni wena yonke lento 
Oludliwano ndlebe luzaku thatha imizuzu e yi 20-30minute.Awuzuku bhatalwa ngoku thatha kwakho 
inxagxeba. 
 
Wenza njani xa lemibuzo I khathaza umthathi ngxaxeba? 
Lumise u dliwano ndlebe,ungamphathisi tyala umthathi ngxaxheba. U vumelekile,u 
kungaqhubekeki umthathi nxaxheba xa engasa ziva mnandi e moyeni. 
 
Yintoni isazi mvumelwano? 
Phambi kokuba u vume u ku thatha ingxagxeba ko lu phando lwazi. Injongo yolutyikityo sivumelwano 
kukunika olunye ulwazi ngolu phando,nokukhusela. Iimfihlo zakho kunye namandla akho okuzigqibela, 
Nokugcina uxanduva kulo ophandayo. Lento ke yenza ukuba lo ophandayo enze ngoku the gca 




Ukuba unayo eminye imibuzo malunga nolu phado lwazi ,nceda u thethe no 
Dr Shannon Odell 
084 556 2778 
shannonodell@yahoo.com 
 
Ukuba ufuna ulwazi ngelungelo lwakho nangoku khuseleka kwakho njengomthathi ngxaxheba ko lu 
phandu lwazi, nceda u thethe ne : contact the UCT Research Ethics Committee 
Mrs Lamees Emjedi 
Research Ethics Committee Administration Supervisor 
E52 Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
021 406 6338 
 


















Informed consent document- English (to be kept by researcher): 
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A study to determine the Palliative Care Needs of Patients with Drug Resistant Tuberculosis in the 
Southern sub-district of Cape Town 
Ask potential participant to recall the: day of the week:   month:  year:  suburb:   
      country:      






The participant has been provided with the information sheet regarding this research study and has been 
given the opportunity to ask questions to clarify any issues or concerns about the study. The participant 
seems to understand what their involvement will involve. To the best of my knowledge, the participant 
has not been hindered by a communication barrier in their understanding and consenting to their 
involvement in this questionnaire, and has been assessed as being competent to give informed consent 
and continue. 
 
Researcher’s name: ________________________________________________________________ 
 
Researcher’s signature: ________________________________________________________________ 
 
Date:   ________________________________________________________________ 
 
Participant’s consent: 
By signing this consent form, I have understood what this research will involve, the time it will take and 
that my answers will not affect my relationship with the counselor/ volunteer or affect my current or 
future care and management. I have been given the opportunity to ask questions where I might have been 
unclear on an issue. I realize that I am allowed to stop the questionnaire at any time if it becomes too 
upsetting for me. 
 
I would like to continue with the questionnaire and give my permission voluntarily to take part. 
 
Participant’s name:   ________________________________________________________________ 
 
Participant’s signature: ________________________________________________________________ 
 
Date:   ________________________________________________________________ 
 
Witness’s name: ________________________________________________________________ 
 
Witness’s signature: ________________________________________________________________ 
 







Ingeligte toestemmingsdokument – Afrikaans (moet deur navorser bewaar word) 
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‘n Studie om die Palliatiewe Versorgingsbehoeftes van Pasiënte met DR-TB in die Suidelike sub-
distrik van Kaapstad te bepaal. 
Ask potential participant to recall the: dag van die week:   maand:  jaar:  woongebied:  
      land:      





Navorser se verklaring: 
Die deelnemer is voorsien van die inligtingsbladsy met betrekking tot die navorsingsstudie en is die 
geleentheid gegun om vrae te vra oor enige sake of voorbehoude oor die studie. Dit lyk of die deelnemer 
verstaan wat hul betrokkenheid sal behels. Na die beste van my wete, is die deelnemer nie verhinder deur 
gebrekkige kommunikasie om te verstaan wat die gee van sy/haar toestemming in die aflê van die vraelys 
behels nie en is gevind om in staat te wees om ingeligte toestemmimg te gee en voort te gaan met die 
studie.  
 
Navorse se naam:   ___________________________________________________________ 
 
Navorser se handtekening: ___________________________________________________________ 
 
Datum:     ___________________________________________________________ 
 
 
Deelnemer se toestemming: 
Deur die teken van hierdie toestemmingsbrief/vorm, verstaan ek wat hierdie navorsing behels, die tyd 
wat dit in beslag sal neem en dat my antwoorde nie my verhouding met die berader/vrywilliges of my 
huidige of toekomstige versorging en behandeling sal beïnvloed nie. Ek is die geleentheid gegee om vrae 
te vra, waar ek onseker was oor ‘n saak. Ek besef dat ek die vraelys enige tyd mag staak, indien dit my te 
erg ontstel. Ek wil graag voortgaan met die vraelys en gee vrywilliglik my toestemming om deel te neem. 
 
Deelnemer se naam:   _______________________________________________________ 
 
Deelnemer se handtekening: _______________________________________________________ 
 
Datum:     _______________________________________________________ 
 
 
Getuie se naam:   _______________________________________________________ 
 
Getuie se handtekening: _______________________________________________________ 
 








Informed consent document (to be kept by researcher)- isiXhosa translation 
 119 
Esisazi sivumelwano sigcinwe ngum phandi lwazi . 
 
U phando ngokufuna u kwazi nge zidingo zesigulane e sine Drug Resistant Southern sub-district of Cape 
Town 
Uyakwazi ukukhumbhula :I nstuku ze veki:   Inyanga:  U nyaka:  I lokisi yakho:  I lizwe 
lwakho:      
Imibuzo mayelana ne phepha lo lwazi nge sazi si vumelwano: 
 
____________________________________________________________________________________ 
I sithembhiso somphandulwazi: 
Umthathi nxaxheba ulinikiwe I phaphe elimnika ulwazi nengcazelo malunga nolu phando lwazi, kweye 
ulinikiwe nethuba loku buza  yonke imi buzo Anayo, kwakunye nezinto angazivamcam ngolu phando. 
Umthathi nxaxheba ujongeka ecacelwe yindima azakuyidlala Malunga nolu phandolwazi. Ngoku qonda 
kwam. Umthathi nxaxheba uye wacaciselwa ngolwimi lwakhe lwenkobe Malunga nendima yakhe 
azakuyidlala kolu phando lwazi, kwaye uhloleke ekwi simo esifanelekileyo ukuba angakwazi ukuphedua 
lemi buzo. 
 
Igama lomphandi lwazi  ___________________________________________________________ 
 
utyikityo yom phandi lwazi ___________________________________________________________ 
 
Umhla:     ___________________________________________________________ 
 
I sazi sivumelwano nomthathi ngxaxheba: 
Ngoku vuma uku thatha ingxaxheba ko lu phando lwazi, lonto I thetha ukuba wazi ngcono nge xesha 
elizo ku funeka ukuze imibuzo iphenduleke yonke, kwaye u cacelwa ukuba ekuthatheni kwakho 
inxaxheba kulu phando lwazi, lonto ayi zo ku phazamise uncedo lwakho e clinic.ucacelwa ukuba ungali 
misa nangeliphi na ixesha oludliwano ndlebe xana ungaziva mnandi . 
 
I gama lomthathi nxaxheba: __________________________________________________________ 
 
utyikityo yomthathi nxaxheba: __________________________________________________________ 
 
Umhla:     __________________________________________________________ 
 
 
Igama le igqina:  __________________________________________________________ 
 
Utyikityo le ingqina:  __________________________________________________________ 
 











at ____________________________________________________ facility. 
 
Many thanks for seeing _______________________________________________________________ 
who, whilst participating in a research study: “A study to determine the Palliative Care Needs of 
Patients with Drug Resistant Tuberculosis in the Southern sub-district of Cape Town” (HREC 





























































































If, whilst administering the questionnaire, the trial participant displays or expresses severe physical, 
emotional or existential distress then he/she will be offered the opportunity to halt the questioning and 
the distress protocol will be implemented: 
i. Try to ascertain the reason for the distress and remain calm 
ii. Acknowledge how the line of questioning might be distressing 
iii. Give the trial participant the opportunity to stop the interview temporarily or withdraw from the 
study entirely  
iv. Reaffirm that withdrawing will not jeopardize further management or care 
v. Recommend referral be made to appropriate health care professional at the nearest clinic for 
management of specific distress. 
vi. If patient consents to referral, make the necessary arrangements 
vii. If the trial participant wishes to continue the questioning when more comfortable, proceed 
viii. Offer further counseling 
ix. Apologize for this line of questioning causing distress 
x. Thank the trial participant for their time  
xi. Contact clinic at a later stage to ensure patient is receiving the necessary management  
 
Similarly, should the interviewer feel that his/her physical safety be in jeopardy or that infection control 
be insufficient, then the questionnaire is to be stopped, and the following procedure followed: 
i. Apologize for having to stop the research questioning 
ii. Explain your concern for safety or infection control 
iii. Enquire whether another time or place could be arranged to continue completing the 
questionnaire 
iv. If yes, then reschedule an interview at a more appropriate location or time, without the validity of 
the answers being affected.  Ensure that adequate corrective measures are instituted. 
v. If no, thank them for their time and reassure them that there would not be any negative 
consequences to their future and ongoing management 
 
In either situation, ensure that it is documented on the questionnaire, by marking the relevant check box 






Indications for DR-TB Treatment Withdrawal 
According to the Department of Health Policy Guidelines on the Management of Drug-Resistant 
Tuberculosis(19): 
Treatment withdrawal is considered when: 
▪ No further drugs or surgery are available  
▪ The patient no longer consents to treatment 
▪ Where treatment has a negligible chance of success and is considered futile eg chronic 
defaulters or causing additional suffering eg in advanced terminal disease. In these instances 
continuing treatment might result in amplification of resistance. 
 
APPENDIX 22 


















(PAS): Para-Aminosalicyclic acid 
(Pto): Prothionamide 
(Z): Pyrazinamide 
(R): Rifampicin 
(S): Streptomycin 
(Trd): Terizidone 
(Th): Thioacetazone 
(Vm): Viomycin 
